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 Introduction  
Tuberculosis (TB) has re-emerged as a major public health problem in the country of Georgia 
following the collapse of the Soviet Union1, 2.  TB case rates in Georgia increased markedly 
following the dissolution of the Soviet Union.  Following implementation of a national TB 
program in Georgia, between 2007 and 2013, the annual incidence and prevalence of TB 
decreased from 149/100,000 to 116/100,000 and from 226/100,000 to 163/100,000, 
respectively. However, TB and especially highly drug resistant TB, remains a major public 
health problem in Georgia 3.  
The country of Georgia is among the 27 high multidrug resistant TB (MDR-TB) burden 
countries as designated by the World Health Organization (WHO) 3. MDR-TB is defined as 
resistance to isoniazid and rifampicin, with or without resistance to other first-line anti-TB 
drugs4, 5. Among the 27 high MDR-TB burden countries the proportion of MDR-TB cases 
with extensively drug resistant TB (XDR-TB) was one of the highest (20%) in Georgia in 
20133. XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any 
fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and 
kanamycin) 4, 5.  Currently, 11% of newly diagnosed cases in Georgia and 38% of retreatment 
cases in Georgia have MDR-TB. 
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Prior to 2012, in Georgia, as in many other high burden TB countries in Eastern Europe, 
patients with infectious TB were diagnosed and treated in specialized inpatient and 
outpatient TB facilities organized by the National Tuberculosis Program (NTP), although 
persons with undiagnosed TB or suspected cases of TB may have been seen at non-TB health 
care facilities and referred to a specialized TB facility later1. Currently in Georgia, TB care is 
provided by diverse non-NTP public and private care providers3.  
 
Nosocomial TB transmission from patients to HCWs has been recognized for many years; the 
risk of transmission is the greatest in facilities with a high burden of infectious TB cases6-11. 
The XDR-TB strains are posing a major public health threat in contexts characterized by a 
limited TB IC measures.  TB infection control (IC) measures in Georgian health care facilities 
(HCFs) have been limited and similar challenges have been seen as is the case in most low 
and middle-income countries (LMICs) which have had very limited introduction of TB IC 
measures.  TB IC measures include administrative, engineering and personal protection 
controls with administrative controls being most important9,12. 
There are no routine programs in place to screen HCWs for latent tuberculosis infection 
(LTBI); only ultraviolet (UV) lights and respirators were available in the specialized TB 
facilities in Georgia1, 13, 6, 10, 14.  A high prevalence of LTBI among HCWs from specialized TB 
facilities was found in Georgia in 20061; 77% of HCWs had a positive result for at least one of 
the two diagnostic tests for LTBI [QuantiFERON-TB Gold In-Tube (QFT-GIT) and 
tuberculin skin test (TST)] and 50% tested positive for both tests1.    
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 The goal of this Ph.D. dissertation is to determine the role of TST and QFT-GIT in the 
assessment of nosocomial TB transmission and implementation of TB IC measures in HCFs in 
the country of Georgia. Evaluating LTBI test conversion rates provides important 
information on TB occupational exposure risks among Georgian HCWs. Also, the use of both 
TST and QFT-GIT LTBI tests allow for the comparison of the two tests. As there is limited 
data on QFT-GIT use in serial testing in high-burden TB countries (i.e., low and middle-
income countries), this dissertation would contribute to the literature in this area.  
Specific aims of the dissertation include:  
1. To determine prevalence and incidence of LTBI and associated risk factors among 
Georgian HCWs 
2. To evaluated the effect of occupational exposure to TB and BCG vaccination history 
on the outcome of TST and QFT-GIT positivity at baseline and on the conversion of 
these tests  
3. To assess determinants of TB IC related behaviors among Georgian HCWs 
We performed a prospective cohort study among HCWs from TB and non-TB facilities in 
Georgia using serial testing of health care workers with two diagnostic tests--the TST and the 
QFT-GIT in 2009 - 2011. The principle hypothesis was that QFT-GIT positivity is more 
likely to be associated with the well established indicators of occupational TB exposure than 
TST positivity among HCWs in Georgia. Furthermore, in July – December 2011 we 
conducted an anonymous survey of Georgian HCWs to provide baseline data on their 
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knowledge, beliefs, and behaviors related to TB IC. The data will be used to inform the 
development and implementation of future TB IC interventions/programs at Georgian HCFs. 
 
Literature Review 
Nosocomial TB Transmission 
 
TB was recognized as an occupation health hazard for HCWs since the 1950s15. Emergence of 
M/XDR-TB and effect of human immunodeficiency virus (HIV) infection on TB epidemics 
resulted in reemergence of TB as an occupational health hazard for HCWs in the early 
1990s15. TB transmission occurs through droplet nuclei aerosolized by patients with TB 
disease and inhaled by other persons. Transmission is most likely to occur from sputum 
smear or culture positive TB patients. The magnitude of nosocomial TB transmission varies 
by setting, occupational group, and TB prevalence in the community, patient population, and 
effectiveness of TB IC measures. The risk is greater when a larger number of patients with 
smear-positive TB are managed in the HCF6, 7, 9-11, 16.  
Transmission of TB in health care settings has been reported from virtually every country in 
the world, regardless of local TB incidence. Most of the studies on nosocmial TB transmission 
in LMICs published since 1990s reported prevelance of LTBI among HCWs  greater than 
40%11. In the same years, prevalence of postive TST among HCWs from high income 
countries (HICs) ranged between 1.8% to 46%17-25.  Risk foactors for the prevalence of LTBI 
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among HCWs are diverse between LMICs and HICs. In LMICs LTBI is typically associated 
with markers of occupational exposure. History of contact with TB patients, working in 
medical wards, and participation in sputum collection and autopsies were independent 
occupational risk factors for LTBI in several studies conducted in LMIC11. Also, markers of 
cummulative exposure, increasing age and years of employment as a HCW, were associated 
with higher prevalence of LTBI in most studies1,11. Studies from HICs more often reported 
association of positive TSTs among HCWs with non-occupational factors - older age, foreign 
birth, bacille Calmette-Guérin (BCG) vaccination, and TB contact outside their work21,23. 
Moreover occupational risk factors including years of employment in health care1, 17, 23, 25, 
particularly in internal21, 22 or respiratory medicine24, and more direct indicators of TB 
exposure including working in HCFs with higher mumber of TB admissions23 and the 
percentage of patients with TBor HIV17 were associated with positive TSTs in HCWs from 
HICs.  
Schwartzman et al. reported a significantly and markedly increased infection risk for 
HCWs26. The relative risk estimate for medical personnel is 13.6 (95% CI: 1.4, 132) in the 
cohort study and 2.6 (95% CI: 1.3, 5.2) in the cross-sectional study26. HCWs vs. non-HCWs 
have 1.5 (95% cinfidence interval (CI): 1.3-1.7) times higher risk of positive TST25. Hospital 
areas with TB patients had 6.3 (95% CI: 0.9–52.8) times higher risk of positive TST compared 
to the non-exposed departments27. Many epidemiological studies reported an association 
between work on wards with TB patients and TB infection and disease27,28-30. Relative risk 
estimates range from 2.1 30 to 10.328.  
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According to a systematic review of TB among HCWs in LMICs, the annual risk of TB 
infection (ARI) ranged from 3.9% to 14.3% among HCWs.10  Another review by Menzies et 
al. published in 2007 reported the median ARI attributable to health care work of 5.8% 
(range 0–11%) in LMICs and of 1.1% (0.2–12%) in HICs.  
Rates of active TB in HCWs were consistently higher than in the general population in all 
LMICs, although findings are variable in HICs11, 31, 32 . In facilities with fewer HCWs per a TB 
patient cared for reported a higher incidence of TB disease. Furthermore, HCWs from TB 
inpatient facilities, general medicine wards, laboratories and emergency rooms had higher 
incidence of TB compared to the general population. HCWs from surgery and obstetrics and 
gynecology departments had a lower active TB incidence. The incidence was lowest in 
administrative staff11.  
TB transmission in HCFs can be significantly reduced with the implementation of effective 
TB IC measures7, 9, 12, 33, 34. The nosocomial transmission of MDR-TB and extensively drug 
resistant TB (XDR-TB) further highlights the need for effective TB IC measures35-37. Dramatic 
nosocomial outbreaks of MDR-TB in HIV infected populations in the ealry 1990s in the US 
fostered further strengthening of administrative, personal and engineering IC measures  in 
many hospitals in HICs11, although since the first recognition of nosocomial TB transmission 
in the 1950s, effective IC measures have been implemented in resource-rich countris.9  
Most HICs screen HCWs periodically for LTBI as part of their TB IC programs9, 38 but this 
practice is unusual in most LMICs9, 34. 
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WHO policy on TB IC identifies a set of activities for national and subnational TB IC. These 
activites include: identification and strengthening of a coordinating body for TB IC, 
development of a comprehensive budgeted plan including budget for human resource 
requirements, monitoring and evaluation of TB IC measures including supervision activities 
and enabling to conduct operational research. The national and sub-national managerial 
activities listed above provide the managerial framework for the implementation of TB IC in 
HCFs. TB IC elements at the facility level are generally implemented based on risk 
assessment and informed by climatic, cultural, cost and programmatic factors. The measures 
at this level also include administrative and environmental controls, and personal protective 
equipment12. These types of control should be implemented together because they 
complement one another.  
While most HICs have successfully implemented TB IC measures9, TB IC measures are 
limited or virtually non-existent in most resource-limited TB endemic countries 1, 10, 14, 39, 40.   
As it is mentioned in the End TB draft strategy developed by the WHO, “Regulatory 
mechanisms essential to ensure effective IC, rational use of tuberculosis diagnostics and 
medicines, mandatory disease notification, functioning vital registration systems, and 
protection of the legal rights of people with tuberculosis remain weak”41.  
Multiple studies suggest that the decline in nosocomial TB transmission observed in specific 
institutions is associated with the rigorous implementation of IC measures 33, 42-45. Reports of 
increased implementation of recommended TB ICs combined with decreased reports of 
outbreaks of TB disease in health-care settings suggest that the recommended controls are 
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effective in reducing and preventing health-care–associated transmission of M. tuberculosis 
46.  Administrative IC measures had a modest impact in LMICs, yet seemed the most effective 
in HICs.11  
HCW training and education regarding LTBI and TB disease is an essential part of managerial 
controls in a TB surveillance and IC program9, 12.  
 
 
Latent Tuberculosis Infection 
 
Ending the tuberculosis epidemic will entail early diagnosis and proper treatment of all cases 
of active tuberculosis as well as a gradual removal of the pool of LTBI in some 2000 million 
people.41  LTBI is defined as a state of persistent immune response to stimulation by 
Mycobacterium tuberculosis antigens without evidence of clinical and radiographic findings 
active TB. A direct measurement tool for LTBI in humans is currently unavailable. The vast 
majority of infected persons has no signs or symptoms of TB.47,48 
In general, tubercle bacilli cannot be recovered from sputum or other sites in latently 
infected persons,49 indicating a low bacillary burden. Based on human pathology data and 
emerging data from nonhuman primates, LTBI appears to represent a spectrum of 
microbiological and pathological states in which the organisms are viable but fail to produce 
respiratory or constitutional symptoms.50 
However, persons with LTBI can progress to active TB at any time, often many years or even 
decades after initial infection,51 thereby serving as a source of new infections. Although 
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identification and treatment of infectious persons are paramount, global TB eradication 
efforts must also focus on detecting and treating cases of LTBI41. According to the Institute of 
Medicine, “to make significant progress toward the elimination of tuberculosis in the United 
States, efforts to prevent cases from occurring must be amplified”.52 Current diagnostic tests 
do not discriminate between LTBI and active TB, and treatment for LTBI requires prolonged 
administration of antibiotics.53 An improved understanding of the host and pathogen 
mechanisms underlying LTBI may yield novel assays which can identify persons at increased 
risk for progression to active disease,54 as well as new drugs to shorten the duration of LTBI 
treatment.55 Active TB can occur soon after initial exposure and infection (i.e., primary 
disease) or after a period of LTBI (reactivation disease). Although reactivation TB cannot be 
differentiated from primary disease on clinical or laboratory grounds, epidemiological studies 
have demonstrated that the majority of active TB cases in the United States and other 
countries with low TB prevalence occur as a result of reactivation of LTBI. The goal of LTBI 
treatment is to prevent reactivation, and this is especially recommended for persons who are 
at increased risk for progression from LTBI to disease.56 Persons at increased risk of 
reactivation of LTBI include those with HIV/AIDS, those receiving immunosuppressive 
treatment, including cancer chemotherapy, systemic steroids, and anti-TNF agents, and those 
with chronic systemic diseases, such as end-stage renal disease, rheumatic disorders, and 
diabetes mellitus.57 Identification and successful treatment of persons with LTBI at risk for 
reactivation are important components of global TB elimination efforts41. 
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 LTBI Diagnostic Tests 
 
Tuberculin Skin Test  
 
The tuberculin skin test is one of the few tests developed in the 19th century that is still in 
present use in clinical medicine. The first tuberculin test material was prepared by Robert 
Koch58; The TST was introduced in 1910 by Mantoux.59  Several factors others than LTBI can 
influence TST’s positivity. Inter subject variability in biological response to tuberculin60, 
interreader variability60, the booster effect 61-64, immune response to nontuberculous 
mycobacterial antigens 65, 66, and previous vaccination with bacillus Calmette-Guerin (BCG) 
can all be responsible for a positive TST result 67-73. BCG vaccination is the main problem in 
interpreting TST results, in particular in countries  where the rate of vaccination is high and 
the prevalence of tuberculosis is low59. One must be cautious in interpreting TST reactions 
because of the potential implications associated with a positive result, such as the need for 
chest radiography and 6- to 9-month preventive chemotherapy, the risk of treatment 
hepatotoxicity, and the anxiety generated in the patient.  
Tuberculin reactivity after BCG vaccination for adults in western countries with a low 
prevalence of TB could therefore differ from that experienced in countries with moderate or 
high prevalence rates,74 The proportion of individuals with a prior BCG vaccination who 
have a positive TST result has been reported to vary from 0% to 90%. Subsequent reactivity 
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of TST can vary depending on BCG dose, manufacturer of the vaccine, age when vaccinated, 
and the interval between vaccination and testing71.  
Several reports from Quebec suggest that BCG vaccination in infancy does not contribute to 
a subsequent positive PPD response, whereas BCG given in childhood or at an older age may 
result in a positive TST71.  
Given such a long history of TST use, it may seem surprising that aspects of interpretation of 
this test remain controversial. However, this reflects changes in the populations affected 
with tuberculosis and their relative frequency of true positive tests from TB infection, and 
false-positive tests associated with bacillus Calmette-Guèrin (BCG) vaccination, or 
nontuberculous mycobacteria, as well as the recent human immunodeficiency virus (HIV) 
epidemic60.   
 
Interferon-gamma Release Assays 
 
For many years the tuberculin skin test (TST) was the only test available for diagnosis of 
LTBI; however, the interferon-gamma release assays (IGRAs), T-cell based assays, have 
become available and provide alternative diagnostic test for LTBI.75 Two commercially 
available IGRAs have been approved for use by the U.S. FDA—the Quanti- FERON-TB Gold 
In-Tube (QFT-GIT) assay (Cellestis Inc., Valencia CA) and the T-SPOT.TB assay (Oxford 
Immunotec, Abingdon, UK). QuantiFERON®-TB Gold In-Tube (IT) is an in vitro diagnostic 
test using a peptidecocktail simulating ESAT-6, CFP-10 and TB7.7(p4) proteins to stimulate 
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cells in heparinised whole blood. Detection of interferon-γ (IFN-γ) by Enzyme-Linked 
Immunosorbent Assay (ELISA) is used to identify in vitro responses to these peptide antigens 
that are associated with Mycobacterium tuberculosis infection. 76 
QuantiFERON®-TB Gold IT is an indirect test for M. tuberculosis infection (including 
disease) and is intended for use in conjunction with risk assessment, radiography and other 
medical and diagnostic evaluations.76 
IGRAs have several advantages over the TST: they require only one visit, are not affected by 
BCG vaccination, have less cross-reaction with non-tuberculous mycobacteria, are less 
subjective in measuring results, and can be repeated without boosting. However, there is a 
lack of data on how IGRAs perform when used for serial testing, especially in low and 
middle-income countries. In 2005, the U.S. Centers for Disease Control (CDC) recommended 
that IGRAs can be used in all settings where the TST has been used, including the serial 
testing of HCWs77. The updated 2010 CDC guidelines caution that ‘‘lenient criterion to 
define IGRA conversion might produce more conversions than are observed with the more 
stringent criteria applied to TSTs. Furthermore, an association between an IGRA conversion 
and subsequent disease risk has not been demonstrated. 
The criteria for interpreting changes in an IGRA that identify new infections remain 
uncertain’.75 Guidelines from Australia advise caution when using IGRAs for HCW 
screening,78 and Canadian guidelines do not recommend the use of IGRAs for serial testing of 
HCWs,79 citing a lack of available data. A World Health Organization (WHO) policy 
statement on the use of IGRAs in low- and middle-income countries indicates that ‘‘data on 
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serial testing and reproducibility of IGRAs, as well as evidence on the predictive value of 
IGRAs in HCWs, are still absent for high-incidence settings".80 
 IGRAs are in vitro blood tests that detect immunologic responses to Mycobacterium 
tuberculosis complex antigens, and have potential for improving LTBI testing.75, 81 IGRAs 
require one patient–provider interaction to obtain results, which can be available within 1 
day and are not affected by prior BCG vaccination.82, 83 The Centers for Disease Control and 
Prevention (CDC, Atlanta, GA) has issued guidance that, for detection of TB infection, 
IGRAs may be used in place of a TST, and IGRAs are preferred for testing BCG-vaccinated 
persons.75 The QuantiFERON-TB Gold In-Tube (QFT-GIT; Cellestis [a Qiagen company], 
Valencia, CA) and T-SPOT.TB (T-SPOT; Oxford Immunotec Ltd., Abingdon, UK) tests are 
U.S. Food and Drug Administration–approved IGRAs for diagnosing TB infection. IGRAs 
perform well for detection of TB infection among contacts of individuals with active 
pulmonary TB.84, 85 However, with the introduction of IGRAs into clinical practice, a broader 
population is being tested including individuals undergoing serial testing in the absence of 
known exposure. Published experience, much of which is from settings of routine clinical 
use with potential selection bias with respect to individuals selected for testing or repeat 
testing, indicates unexpectedly high rates of IGRA positivity, conversion (change from a 
negative to positive), and reversion (change from positive to negative)86-91 20. 
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Methods  
Study Setting and Population 
 
This dissertation included two studies that examined a subset of specific aims. The first study 
- a prospective cohort study was conducted from 2009 – 2011. HCWs from the Georgian 
National TB Program (NTP), including the National Center for Tuberculosis and Lung 
Diseases (NCTLD) in Tbilisi, its affiliated TB outpatient clinics from whole country, as well 
as HCWs from non-TB primary health care centers (PHC) were eligible to enroll. An HCW 
was defined as anyone working in a health care setting, regardless of direct patient contact. 
The PHCs are not specialized in TB patient care but commonly refer TB suspects to the NTP.  
Inclusion criteria were age >18 years old, HCW in the country of Georgia, and provision of 
written informed consent. Exclusion criteria were history of active TB and allergy to the 
purified protein derivative used in the TST. Our target population consisted of 4,485 HCWs 
including physicians, nurses, and administrative and technical staff. One-thousand-four-
hundred HCWs worked for the NTP and 3,085 HCWs were from PHCs. To estimate 
association between indicators of occupational TB exposure and positive results of the LTBI 
dianostic tests (TST and QFT-GIT) 95% confidence level and 80% power was used.  Sample 
size was calculated by EpiInfo Version 6 Statcalc. This was a voluntary study. A convenience 
sampling method was used. HCWs were approached with information about the study at 
their place of work and were enrolled if they agreed to participate and provided informed 
consent. Initially, HCWs completed a questionnaire with demographic information, medical 
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history, and employment history, and then were tested for LTBI with QFT-GIT and TST. 
HCWs who tested positive for LTBI by either test were referred to the NCTLD for evaluation 
to rule out active TB. This evaluation included chest x-ray and symptoms screening. As it is 
not the standard of care in Georgia, no HCWs were treated for latent TB infection.  
The second study - a population-based HCWs survey about TB and TB IC was conducted 
between July-December 2011 among HCWs in Georgia. Target population for this survey 
was the same as for the prior study, HCWs from the Georgian NTP, including NCTLD in 
Tbilisi, its affiliated TB outpatient clinics from whole country, as well as HCWs from non-TB 
PHCs were eligible to enroll. Inclusion criteria were age >18 years old and being a HCW. 
Sample size was calculated accounting for 95% confidence level, 5% margin of error, and 
estimated 70% of a particular response to the survey questionnaire. HCWs were approached 
with information about the survey at their place of work and were enrolled if they agreed to 
participate 
 
Ethics Statement 
 
 
The study was approved by the Emory University Institutional Review Board and Georgian 
NCTLD Ethics Committee. For the prospective cohort study HCWs enrolled into the study 
provided written informed consent in their native Georgian language, but for the anonymous 
survey only oral consent was provided.  
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 Data Collection 
 
Data on potential risk factors for and prevalence and incidence of LTBI were collected using 
a questionnaire and a data collection form. Data on determinants of HCWs behaviors related 
to TB IC were collected via an anonymous questionnaire.    
As part of the prospective cohort study on rates and risk factors for LTBI among Georgian 
HCWs, HCWs and medical students enrolled into the study completed a questionnaire. The 
questionnaire included questions regarding demographic information (date of birth, gender, 
country of birth, race, ethnicity), medical history (history of BCG vaccination, information 
about community TB exposure, history of tuberculin skin testing, history of TB disease), 
employment history (occupation, number of years employed as a HCW, or number of years 
as a medical student, job title). The questionnaires were available for participants to fill out in 
their native Georgian language of Kartuli (Appendix 1).  
After completing the questionnaire, two diagnostic tests for LTBI were performed: the TST 
and the QFT-3G test. The tests results were recorded in a data collection form (Appendix 2).  
As part of the population based HCWs survey about TB and TB IC, an anonymous self-
administered 55-question survey was provided to all participants in the Georgian language 
(Kartuli) (Appendix 3). The survey was piloted with 10 HCWs from the NCTLD; these 
HCWs were not included in the final sample. The survey was developed based on the Health 
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Belief Model (HBM) conceptual framework.92-95 The survey collected information about 
respondents’ TB knowledge, their health-related behaviors, and willingness to engage in 
health-related behavioral change with respect to the following: respirator use, UV lights, 
willingness to be annually screened for LTBI, and willingness to be treated for LTBI if tested 
positive by LTBI diagnostic tests. In addition, the survey measured the following HBM 
constructs: perceived susceptibility to and perceived severity of LTBI and TB disease 
including multi and extensively drug-resistant (M/XDR) TB, perceived benefits of IC 
measures, perceived barriers to implementing IC measures, and cues to action such as 
availability of respirators and instructions from managers related to using the respirators. We 
also asked various socio-demographic questions in order to further characterize the study 
population.    
 
Laboratory Methods 
 
QuantiFERON-TB Gold In-Tube Test 
 
 
Three ml of blood was drawn (Appendix 4) for the QFT-GIT test, which was performed 
according to the manufacturer’s instructions76 and as previously described96. The assay 
involved 2 stages: incubation of whole blood with antigens, and measurement of IFN-γ 
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production in harvested plasma by enzyme-linked immunosorbent assay [ELISA]. Venous 
blood was directly collected into three 1-mL heparin-containing tubes. One tube contained 
only heparin as negative control, another also contained the T-cell mitogen 
phytohemagglutinin as positive control, and the third tube had overlapping peptides 
representing the entire sequences of ESAT-6 and CFP-10, and another peptide representing a 
portion of TB7.7. 20 Within 1 to 12 hours of blood draw, the tubes were incubated at 37°C. 
After 24 hours of incubation, the tubes were centrifuged and plasma harvested and stored at 
4°C for two weeks or frozen at –70°C until the ELISA is performed. The amount of IFN-γ was 
quantified using an ELISA.  The IFN-γ values (IU/mL) for tuberculosis-specific antigens and 
mitogen was corrected for background by subtracting the value obtained for the respective 
negative control. The entire QuantiFERON-TB 3G assay is described in Appendix 5.  IFN-γ 
values > 10 IU/ml were treated as 10 IU/ml. Repeat QFT-GIT testing was performed on 
participants 6–26 months after baseline testing. QFT-GIT was performed on all participants 
who underwent repeat testing. As recommended by the manufacturer76 and the CDC,75 the 
QFT-GIT result was defined as positive if the response to the TB antigens minus the negative 
control was ≥0.35 IU/ml and >25% of the negative control, negative if these criteria were not 
met, and indeterminate if either the negative control had a result of >8 IU/ml or if the 
positive control had a result of, < 0.5 IU/ml75. According to CDC guidelines, a QFT-GIT 
conversion was defined as a baseline interferon-gamma (IFN-γ), 0.35 IU/ml and a follow-up 
IFN-γ level ≥0.35 IU/ml, without any consideration of the magnitude in change of the IFN-γ 
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response 75. A QFT-GIT reversion was defined as a baseline IFN-γ ≥0.35 IU/ ml and a follow-
up IFN-γ level <0.35 IU/ml.  
 
Tuberculin Skin Testing 
 
 
The TST was performed using the Mantoux method97,96 and read 48–72 hours after 
placement. The TST was placed intradermally in the volar aspect of the left forearm using a 
sterile tuberculin syringe using 5 tuberculin units (TU) or 0.1 ml of PPD (Tubersol H, 
Connaught; Swiftwater, PA, USA). Study participants were instructed to return to have the 
TST read 48 to 72 hours after placement.  The amount of induration (in mm) was recorded 
on the data collection form.  Readings were recorded in whole numbers and the reading was 
rounded up to the next whole number (e.g., for a reading between 15 and 16 mm of 
induration, 16 mm of induration will be recorded). The research staff was trained on 
tuberculin skin testing.  According to the American Thoracic Society (ATS) and CDC 
guidelines, a TST was defined as positive if the induration in HCWs was ≥10 mm, and a TST 
conversion  was defined as a change in induration from <10 mm to ≥10 mm, with an increase 
of ≥10 mm within 2 years 75, 97. Only patients with a negative baseline TST had repeat TST 
testing performed at follow up. Repeat testing was performed over a range of 6–26 months 
due to limited research study staff and inability to test large numbers of HCWs 
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simultaneously. Due to limited research study staff and limited resources, not all HCWs were 
offered repeat testing. Repeat testing was performed by convenience sampling. 
 
Study Measures and Definitions 
For determination of the prevalence of a positive TST result, we included participants who 
had TST performed in our study or reported prior history of positive TST (n= 308). 
Tuberculin skin testing was performed using the Mantoux method98,97.  A positive TST was 
defined as induration ≥10 mm97,75. Once a health care worker had a positive TST (induration 
of >10 mm), further testing using the TST was no performed. 60. Georgian HCWs were 
assumed to stay TST positive once tested positive with TST (induration ≥10 mm) due to 
steady risk of occupational TB exposure and nonexistence of LTBI preventive therapy for 
HCWs in Georgia1.  
For determination of prevalence of positive QFT-GIT, we included participants who had 
QFT-GIT measured (n= 319). A positive QFT-GIT result was defined based on manufacturer 
recommendations and as previously published99.  A result was considered positive if the 
response (interferon-gamma release) to the TB antigens minus the negative control was ≥0.35 
IU/ml and >25% of the negative control, negative if these criteria were not met, and 
indeterminate if either the negative control had a result of >8 IU/ml or if the positive control 
had a result of, 0.5 IU/ml75. 
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Occupational TB exposure frequency was categorized as daily (contact ≥ 5 days per week), 
frequent (contact < 5 days per week and ≥ twice per month), rare (contact < twice per month 
and ≥ once per 3 months), and very rare (contact < once per 3 months). For multivariate 
logistic regression analysis the occupational TB exposure variable was later dichotomized in 
two ways:  frequent occupational TB exposure (defined as contact ≥ twice per month) 
opposed to rare occupational TB exposure (defined as contact < twice per month and daily 
occupational TB exposure (defined as contact ≥ 5 days per week) opposed to less than daily 
occupational TB exposure (defined as contact < 5 days per week). 
Five-point Likert-type scales were used to assess HCWs’ beliefs and behaviors.100, 101 
Perceived susceptibility to TB infection was measured using a five-level variable where 1 
indicated no perceived possibility and 5 indicated very good chance of being infected with 
TB. Perceived severity of TB infection was also assessed using a five-level variable where 1 
indicated strong agreement and 5 indicated strong disagreement with the statements of 
concerns about acquiring LTBI and TB disease. 
 
Statistical Considerations 
 
Data were collected and entered into a REDCap database.  REDCap (Research Electronic 
Data Capture) is a secure, web-based application designed to support data capture for 
research studies102. Statistical analysis was performed in IBM SPSS Statistics version 19.  
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Products of the analysis included prevalence estimates of LTBI among HCWs enrolled, 
estimates of the LTBI diagnoistic test (TST and QFT-3G) results and conversion rates (from a 
negative test result to a positive test result), agreement between the diagnostic tests (TST and 
QFT-3G), and comparison of the tests (TST and QFT-3G)  results with respect to their 
association with risk factors. Furthermore, results of the analysis included estimates of 
knowledge of TB, beliefs about TB and TB IC and IC releated behaiviours, and determinats of 
TB IC realted behaiviors among Georgian HCWs.  
Agreement between the two diagnostic tests for LTBI (TST and QFT-GIT) was determined 
using the kappa (κ), where κ > 0.75 represents excellent agreement, κ = 0.4-0.75 represents 
fair to good agreement, and κ <0.4 represents poor agreement 103.  
Multivariate analysis was performed using logistic regression modeling with outcomes of TST 
positivity, QFT-GIT positivity, and discordant LTBI test results TST positive / QFT-GIT 
negative group. Participants were included in these models if they had measured TST (or 
history of positive TST) and measured QFT-GIT. The same participants were included in the 
models for QFT-GIT positive and TST positive. The purpose of the multivariate model was to 
estimate relationship between well established indicators of occupational TB exposure and 
positive results of the LTBI diagnostic tests (TST and QFT-GIT) among HCWs in Georgian 
HCFs. Demographic information, BCG vaccination history, and the set of indicators of TB 
exposure at work and outside the work were defined in the multivariate model to provide 
the largest model to be initially considered. Collinearity was assessed for multivariable 
models, variables with significant collinearity were removed from final models. Colliniarity 
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was assessed using the “/statistics=defaults tol” subcommand in the IBM SPSS Statistics 
version 19.  Variables with the “tolerance” values < 0.10 and the the variance inflation factor 
(VIF) values 10 < were excluded from the final model. The “tolerance” is an indication of the 
percent of variance in the predictor that cannot be accounted for by the other predictors, 
hence very small values indicate that a predictor is redundant. The VIF is (1 / tolerance)104. 
Interaction terms were created based on biologic plausibility and were tested individually for 
significance with the Likelihood Ratio Test105. 
We used a backward elimination procedure for removing variables. Variables included in the 
final multivariate models were chosen on the basis of biologic plausibility and statistical 
significance of their association with the outcomes. Variables with potential confounding 
effect were also kept in the final model.  A p-value ≤ 0.05 was defined as statistically 
significant. To analyze how the final model predicted the categorical outcomes we used the 
Hosmer and Lemeshow goodness of fit test106. Cases with studentized residual values greater 
than 2.5 were inspected in further detail to determine why these cases were outliers and 
were removed from the analysis if this was deemed necessary106.  
Incidence rates for TST and QFT-GIT conversion (in 100 person/years) were determined by 
dividing the number of events by the total amount of person-time contributed by those who 
were negative at time of first testing and accounting for the time to follow-up testing. Risk 
factors for TST and QFT-GIT conversion were determined by univariate logistic regression 
analysis and multivariate logistic regression analysis. 
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Proportions of concordant results of the two diagnostic tests were compared between HCWs 
with a bacillus Calmette-Guerin (BCG) scar vs. no BCG scar and between HCWs with self-
reported frequent (≥ twice a month) occupational TB exposure vs. those who saw TB patients 
rarely (< twice a month). The proportions were compared by two-proportion z-test20. 
Proportions of positive QFT-GIT at baseline and repeated testing were also compared among 
HCWs with self reported frequent occupation TB exposure vs. those who reported rare TB 
exposure at work. The proportions were compared by McNemar’s test20.  
For determination of estimates of HCWs knowledge of TB, their beliefs about TB and TB IC, 
and TB IC related behaviors we first calculated frequency distributions; if < 10% of 
participants responded to a question item, that item was excluded from further analysis. 
Five-level variables measuring HCWs beliefs about TB IC measures were reduced to three-
level variables for multivariate analysis. We used binomial logistic regression to estimate the 
association between HCW demographic characteristics and knowledge of TB; ordinal (when 
proportional odds assumption was met) or multinomial logistic regression were used to 
estimate the association between HCW’s beliefs and their IC related behaviors.105 In 
multivariable models we adjusted for variables that met statistical and epidemiological 
criteria105 and were congruent with the HBM framework. Initially the largest multivariate 
model was reduced to the final multivariate model by a backward elimination procedure. 
Collinearity was assessed for multivariable models, variables with significant collinearity 
were removed from final models. Colliniarity was assessed using the “/statistics=defaults 
tol” subcommand in the IBM SPSS Statistics version 19.  We used the Mann-Whitney U-test 
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to compare the median scores of HCWs’ beliefs among two independent groups – HCWs 
who answered a TB related knowledge question correctly and HCWs who answered the 
question incorrectly.107 
Results 
Study Population 
 
Three-hundred-nineteen Georgian HCWs were enrolled in the prospective study (Figure 1); 
all enrolled had a QFT-GIT performed. Fifty-nine HCWs did not have a TST performed (48 
participants reported a prior positive TST in the past and 11 refused to have a TST done). 
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Figure 1. Enrollment and follow-up of participants
NOTE. HCW, HCWs; QFT-GIT, QuantiFERON-TB Gold In-tube assay; TST, tuberculin skin 
test 
The characteristics of the study population (n=319) are described in Table 1. The majority of 
the participants were female (81%), reflecting makeup of HCWs at the NTP and affiliated 
institutions. The mean age was 41 years (standard deviation [SD], 11.4 years). The majority of 
HCWs in our study were from Tbilisi (86%), the capital of Georgia. One hundred ninety 
three (60%) participants worked in specialized TB facilities, and 116 (39%) worked in non-
TB facilities.  Fifty percent of the HCWs reported frequent TB exposure at work (contact ≥ 
HCWs enrolled and 
had baseline QFT-GIT
(n=319)
Refused TST 
(n=11)
Had baseline QFT-GIT / TST 
(or history of positive TST) 
(n=308)
No follow-up QFT-
GIT / No follow-up 
TST; logistic reasons
(n=140)
Had follow-up QFT-
GIT / Refused follow-
up TST (although 
indicated)
(n=5)
Had follow-up 
QFT-GIT and TST 
(if indicated) 
(n=163)
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twice per month) as opposed to rare TB exposure at work (contact ≤ once a month).  The 
mean number of years in health care was 17.0 (SD, 12.6). 
Table 1. Characteristics of the study population (N=319) 
Characteristic No. (%)   
Demographic Characteristic 
Age, y 
18-32 84 (26 %) 
33-41 76 (24 %) 
42-49 81 (25 %) 
≥ 50 78 (25 %) 
Female Gender 259 (81 %) 
Georgian ethnicity 305 (96 %) 
Education 
Graduate school 230 (72 %) 
Undergraduate 68 (21%) 
Secondary school or less 21 (4 %) 
Self reported positive history of BCG vaccination  285 (89 %) 
BCG Scar by inspection 244 (77 %) 
Employment Characteristics 
HCW Employment Location 
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Tbilisi 274 (86 %) 
Other Locations 45 (14 %) 
Health care facility 
TB inpatient facility 121 (38 %) 
TB outpatient facility 72 (23 %) 
Non-TB health facility 126 (39 %) 
Occupation  
Administrative staff 92 (29 %) 
Laboratory Worker 22 (7 %) 
Medical students 14 (4 %) 
Nurses 51 (16 %) 
Physicians 116 (36 %) 
Other 24 (8 %) 
Years working in health care  
0-4 71 (22 %) 
5-14 81 (25 %) 
15-24 72 (23 %) 
>25 95 (30 %) 
Occupational TB exposure frequency  
Daily (≥ 5 days a week) 101 (32%) 
Frequent (< 5 days a week and ≥ twice a month) 58 (18 %) 
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Rare ( ≤ once a month and ≥ once a quarter) 61 (19 %) 
Very rare ( < once a quarter) 99 (31 %) 
Positive history of TB contact outside their work 74 (23 %) 
Note. BCG, HCW, health care worker; TB, tuberculosis 
 
For assessment of determinants of TB IC related behaviors among Georgian HCWs  a total of 
298 HCWs were approached in the population based survey to enroll in the study with 58 
(19 %) refusing to participate. The characteristics of the study population (n=240) are 
described in Table 2. The mean age of HCWs who participated was 44.3 years (standard 
deviation (SD) 11.4 years). The majority of the participants were female (90%) again 
reflecting the gender distribution of HCWs at the NTP and affiliated institutions. Nearly half 
(54%) HCWs were from the capital city, Tbilisi. Fifty-seven percent of the HCWs worked at 
specialized TB facilities. Respirators were available most of the time for only 65% of HCWs.  
Forty-eight percent were physicians and 39% were nurses. The mean number of years in 
health care was 19.7 (SD 10.9 years). 
Table 2. Characteristics of the study population (N=240) 
Characteristic No. (%) 
Demographic Characteristic 
Age, y 
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≤ 25 59 (25 %) 
36 – 44 59 (25 %) 
45 – 51 59 (25 %) 
> 60  57 (24 %) 
Data missing 6 (2 %) 
Female Gender 216 (90 %) 
Employment Characteristics 
Location of HCW employment 
Tbilisi 130 (54 %) 
Other Locations 110 (46 %) 
Health Facility 
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TB Facility 136 (57 %) 
Non-TB health facility 104 (43 %) 
Respirator Is available (most of the time)  
Inpatient TB facility 35 (92 %) 
Outpatient TB facility 77 (79 %) 
Non-TB health facility 45 (45 %) 
Works primarily with TB patients  136 (57 %) 
Occupation 
Physician 114 (48 %) 
Nurse 94 (39 %) 
Other 27 (11 %) 
Missing 5 (2 %) 
Years working in health care  
≤ 5 26 (11 %) 
6-20 98 (41 %) 
21-34 80 (33 %) 
35 ≤ 22 (9 %) 
Data missing 14 (6 %) 
Note. BCG, HCW, health care worker; TB, tuberculosis 
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Prevalence of TST and QFT-GIT Positivity 
 
 
The prevalence of a positive TST at baseline was significantly higher among health care 
worker than the prevalence of a positive QFT-GIT: 63% (193/308) for TST vs. 46% (147/319) 
for the QFT-GIT (OR =1.84, 95% CI 1.33-2.53, p<0.001). The prevalence having both 
diagnostic tests positive was 39% (121/308). The prevalence of LTBI by any of the two 
diagnostic tests being positive was 69% (219/319). Among HCWs who worked in TB 
facilities, 107 of 193 (55%) had a positive QFT-GIT vs. 40 of 126 (32%) of HCWs working in 
non-TB facilities (OR =2.68, 95% CI 1.67-4.28, p<0.0001). Among HCWs working in TB 
facilities, 128 of 188 (68%) had positive TST vs. 65 of 120 (54%) of those working in non-TB 
facilities (OR =1.8, 95% CI 1.13-2.90, p<0.02).   
 
Risk factors for LTBI prevalence 
 
 
In univariate analysis, risk factors for a positive diagnostic test for LTBI included: frequent 
(contact ≥ twice per month) occupational TB exposure (TST: OR 1.6, 95% CI 1.01-2.56, QFT-
GIT: OR 3.1, 95% CI 1.95-4.87), increasing age (TST: OR 1.28, 95% CI 1.04-1.57, QFT-GIT: 
OR 1.39, 95% CI 1.14-1.70), and working in TB HCF (TST: OR 1.8, 95% CI 1.13-2.89, QFT-
GIT OR 2.68, 95% CI 1.67-4.28) (Table 3).  
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NOTE. TST, Tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-tube assay; Frequent, 
contact with TB patients ≥ twice per month; Rare, contact with TB patients < twice per 
month; a Outlier cases were removed from the analysis; b Statistically significant effect 
 
In multivariate analysis, increasing age was associated with a positive TST result. HCWs in 
age group of 33-41 years (aOR 3.63, 95% CI 1.65-7.97), HCWs in age group of 42-49 years 
(aOR 2.77, 95% CI 1.29-5.95) and HCWs in age group of ≥ 50 years (aOR 3.91, 95% CI 1.69-
9.04) were more likely to have positive TST at baseline compared to HCWs in age group of 
18-32 year. (Table 3). In multivariate analysis to independent risk factors associated with a 
positive QFT-GIT, HCWs who reported frequent (≥ twice per month) contact with TB 
patients (aOR 3.53; 95% CI 1.55-8.06) compared to HCWs with uncommon (< twice per 
month) contact with TB patients were more likely to have positive QFT-GIT at baseline. 
Table 3. Univariate analysis for risk factors for a positive TST and QFT-GIT among 
Georgian HCWs 
Characteristic Positive TST  
(n=305)a 
Positive QFT-GIT  
(n=317)a 
aOR (95% CI)  aOR (95% CI)  
Frequent vs. rare  
contact with TB patients  
1.6 (1.01-2.56) b 3.1 (1.95-4.87) b 
Age, years  1.28 (1.04-1.57) b 1.39 (1.14-1.70) b 
TB HCF vs. Non-TB HCF 1.8 (1.13-2.89) b 2.68 (1.67-4.28) b 
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Also, HCWs in age group of 33-41 years (aOR 3.36; 95% CI 1.47-7.68), HCWs in age group of 
42-49 years (aOR 4.26; 95% CI 1.73-10.52), and HCWs with age ≥ 50 years (aOR 5.25, 95% 
CI 1.67-16.45) compared to HCWs in age group of 18-32 years were more likely to have 
positive QFT-GIT at baseline (Table 4). 
Table 4. Multivariate analysis for risk factors for a positive TST and QFT-GIT among 
Georgian HCWs 
Characteristic Positive TST  
(n=305)a 
Positive QFT-GIT  
(n=317)a 
aOR (95% CI)  aOR (95% CI)  
Frequent vs. rare  
contact with TB patients  
1.03 (0.43 - 2.46)  3.53 (1.55 – 8.06)b 
Age, years    
33-41 vs. 18-32 3.63 (1.65-7.97)b 3.36 (1.47 – 7.68) b 
42-49 vs. 18-32 2.77 (1.29-5.95) b 4.26 (1.73 – 10.52) b 
≥ 50 vs. 18-32 3.91(1.69-9.04) b 5.25 (1.67 – 16.45) b 
 
NOTE. TST, Tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-tube assay; Frequent, 
contact with TB patients ≥ twice per month; Rare, contact with TB patients < twice per 
month; a Outlier cases were removed from the analysis; b Statistically significant effect 
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TST and QFT-GIT Conversion Rates  
 
 
Among the 163 HCWs who had QFT-GIT and TST (or positive history of TST) performed at 
baseline and had repeated testing, 81 (49.7%) were susceptible to QFT-GIT conversion 
(negative QFT-GIT at baseline) and 46 (28.2%) were susceptible to TST conversion (negative 
TST at baseline) (Figure 2). The median time from baseline to repeat LTBI testing was 69 
weeks (range 10-112 weeks). QFT-GIT conversions were documented among 24 (29.6%) of 
81 HCWs.  TST conversions occurred in 19 (41.3%) of 46 HCWs (Figure 2).   
The conversion rate by QFT-GIT regardless of baseline TST result was 23.0/100 person-years.  
The conversion rate by TST regardless of baseline QFT-GIT result was 31.2/100 person-years.  
The conversion rate by either test among those who had concordantly negative TST and 
QFT-GIT results at baseline (n=39) was 28.6/100 person-years (26.7/100 person-years for TST 
conversion and 15.3/100 person-years for QFT-GIT conversion). QFT-GIT reversion 
occurred in 12 (14.6%) of 82 HCWs with positive QFT-GIT at baseline, and a reversion rate 
by QFT-GIT was 11.1/100 person-years (Figure 2).
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Figure 2. Results of Diagnostic tests for Latent TB Infection among HCWs, who underwent serial testing:  Conversions and Reversions 
HCW, health care worker; QFT-GIT, QuantiFERON-TB Gold In-tube assay; TST, tuberculin skin test 
HCWs enrolled and had baseline QFT-GIT and TST 
(or history of a prior positive TST)
(n=163)
Negative QFT-GIT at baseline
(n=81)
Negative TST at 
baseline (n=39)
TST 
conversions 
(n=14)
QFT-GIT 
conversions
(n=8)
Positive TST at baseline (or 
history of positive TST) (n=42)
QFT-GIT 
conversion
(n=16)
Positive QFT-GIT at baseline
(n=82)
Negative TST at 
baseline (n=7)
QFT-GIT 
Reversion 
(n=2)
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Risk factors for TST and QFT-GIT conversion 
 
 
Sixteen (84%) of 19 TST conversions and 19 (79%) of 24 QFT-GIT conversions occurred 
among HCWs, who worked at TB facilities.  In univariate analysis, there were no variables 
that were significantly associated with a TST conversion (Table 5). Age per year (OR=1.09, 
95% CI 1.03-1.16) and BCG scar (OR=0.31, 95% CI 0.10-0.96) were associated with QFT-GIT 
conversion, in univariate analysis (Table 5). 
Table 5. Univariate analysis for latent tuberculosis infection (LTBI) diagnostic test (TST and 
QFT-GIT) conversion. 
Characteristic TST conversion 
(regardless of QFT-GIT) 
(18/44) a  
QFT-GIT conversion 
(regardless of TST) 
(23/80) a 
Adjusted OR (95% CI)  Adjusted OR (95% CI)  
Frequent vs. rare contact 
with TB patients 
3.0 (0.78-11.60)  1.2 (0.45-3.26)  
Age in years  1.0 (0.97-1.10) 1.1 (1.03-1.16)b 
TB HCF vs. non-TB HCF 3.6 (0.66 - 19.26) 1.5 (0.49-4.79) 
BCG Scare 3.0 (0.54-16.24) 0.3 (0.10-0.96) b 
NOTE. Frequent contact is contact with TB patients ≥ twice per month; Rare contact is 
contact with TB patients < twice per month; TST, tuberculin skin test; QFT-GIT, 
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QuantiFERRON TB Gold In-tube test; an Outlier cases were removed from the analysis; b 
Statistically significant effect 
 
In multivariate analyzes, there were no variables that were significantly associated with a 
TST conversion (Table 6). Increasing age per year (OR 1.14, 95% CI 1.02-1.27) was an 
independent risk factor associated with QFT-GIT conversion; BCG vaccination scar (OR 
0.16, 95% CI 1.03-0.79) was associated with a decreased risk of conversion, in multivariate 
analysis (Table 6).  
Table 6. Multivariate analysis for latent tuberculosis infection (LTBI) diagnostic test (QFT-
GIT and TST) conversion. 
Characteristic TST conversion 
(regardless of QFT-GIT) 
(19/44) a  
QFT-GIT conversion 
(regardless of TST) 
(23/80) a 
Adjusted OR (95% CI)  Adjusted OR (95% CI)  
Frequent vs. rare contact 
with TB patients 
3.07(0.21-43.43)  1.12 (0.17-7.18)  
Age in years  0.98 (0.85-1.12) 1.14 (1.02-1.27)b 
BCG Scare 8.29 (0.60-114.03) 0.16 (0.03-0.79) b 
 NOTE. Frequent contact is contact with TB patients ≥ twice per month; Rare contact is 
contact with TB patients < twice per month; TST, tuberculin skin test; QFT-GIT, 
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QuantiFERRON TB Gold In-tube test; a Outlier cases were removed from the analysis; b 
Statistically significant effect 
Consistently Positive QFT-GIT 
 
Among 163 HCWs, who underwent serial testing, 70 (43%) had positive QFT-GIT results 
both at baseline and repeated testing.  The proportion of HCWs with consistently positive 
QFT-GIT results on both rounds of LTBI testing was higher among HCWs with frequent (≥ 
twice per month) TB exposure at work compared to HCWs with rare (< twice per month) 
occupation TB exposure (48% vs. 34%, p<0.001) (Table 7).  
Table 7. Consistently Positive QFT-GIT 
Characteristic Frequent Contact 
(n=107) 
Rare Contact  
(n=56) 
No. (%) No. (%) 
Consistently Positive QFT-GIT 51 (47.7) 19 (33.9) 
NOTE. Frequent contact is contact with TB patients ≥ twice per month; Rare contact is 
contact with TB patients < twice per month; QFT-GIT, QuantiFERRON TB Gold In-tube test 
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Agreement between the Diagnostic Tests for Latent TB Infection (LTBI) 
 
At baseline there was fair concordance between the TST and QFT-GIT [κ] =0.40, p<0.01 
Agreement between the two diagnostic tests for LTBI was 70% (214/308); with 30% (93/308) 
of tests concordantly negative, 39% (121/308) tests concordantly positive.  At repeated 
testing, there was poor concordance between the TST and QFT-GIT [κ] =0.37, p<0.01. 
Agreement between the two diagnostic tests for LTBI was 71.8% (117/163); with 15% 
(25/163) of tests concordantly negative, 56% (92/163) tests concordantly positive.  
We found higher proportion of concordant results between the two diagnostic tests for LTBI 
among HCWs with BCG vaccination (documented by the presence of a BCG scare) compared 
to HCWs who did not have the presence of a BCG vaccination scar at baseline (66% vs. 81%, 
p<0.02, n=308). We also found high proportion of concordant results between two diagnostic 
tests for LTBI among HCWs with BCG vaccination (documented by the presence of a BCG 
scare) compared to HCWs who did not have the presence of a BCG vaccination scar at 
repeated testing (79% vs. 70%, p<0.27, n=163). 
There was no significant differences between the results of the two diagnostic tests for LTBI 
among HCWs with frequent (≥ twice a month) occupational TB exposure compared to those 
HCWs who saw TB patients rarely (< twice a month) both at baseline (74% vs. 65%, p<0.08, 
n=308) and repeated testing (72% vs. 71%, p<0.94, n=163).  
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Risk factors for discordant results between TST and QFT-GIT 
 
At baseline, discordant resutls between TST and QFT-GIT was 30% (94/308); with 23% 
(72/308) TST positive and QFT-GIT negative, and 7% (22/308) QFT-GIT positive and TST 
negative.  At repeated testing, discordant resutls between TST and QFT-GIT was 28% 
(46/163); with 27% (44/163) TST positive and QFT-GIT negative, and 1% (2/163) QFT-GIT 
positive and TST negative.  
In multivariate analysis, we found that the HCWs with discordant LTBI test results TST 
positive / QFT-GIT negative group, were less likely to report frequent (≥ twice per month) 
occupational TB exposure (aOR: 0.3, 95% CI: 0.12-0.85) and were more likely to have BCG 
vaccination scar found by inspection (aOR: 2.6, 95% CI: 1.12-5.83) compared to the HCWs 
with concordant LTBI test results (n=214) at baseline LTBI screening. 
In multivariate analysis, only increasing age was in association with discordant LTBI 
diagnostic test results at repeated testing; risk of TST-positive / QFT-GIT negative results 
compared to concordant results the LTBI diagnostic tests (n=117) was lower among HCWs in 
age group 42-49 years vs. HCWs in age group 18-32 years (aOR: 0.24, 95% CI: 0.07-0.84) and 
among HCWs with age ≥ 50 years vs. HCWs in age group 18-32 years (aOR: 0.04, 95% CI: 
0.01-0.26).  
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Active TB Disease 
 
 
Only one HCW was diagnosed with active TB disease after symptom screen and chest x-ray 
at time of LTBI testing.  Three HCWs did develop active disease during this study.  These 
HCWs had tested positive both by TST and QFT within 12 months before being diagnosed 
with active TB. It is expected that TB cases are under-reported among HCWs to the 
NCTLD/NTP TB surveillance department due to the stigma associated with having TB 
disease. It is expected that all that all diagnosed TB cases are notified to the NCTBLD/NTP 
TB surveillance department. 
 
 
HCWs Knowledge about TB 
 
The HCW overall average knowledge score was 61%. HCWs, who worked with TB patients, 
knew more about TB (69% overall average score) compared with HCWs, who did not 
(49.16% overall average score; P < .01). Nearly all HCWs (98%) knew that TB is transmitted 
by an airborne route, and 70% of HCWs knew epidemiological, clinical, and laboratory 
characteristics of LTBI. However, only 43% of HCWs knew the risk of LTBI progression to 
TB disease, and only 30% were able to identify correctly high-risk groups for LTBI 
progression to TB disease. The majority of HCWs (85%) knew the preferred regimen for 
LTBI treatment, but fewer (66%) knew the justification for latent TB therapy. 
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 HCWs Beliefs about LTBI and TB IC 
 
With respect to HCWs, perceived threat of TB infection and perceived benefits and barriers 
of TB IC, 53% of HCWs in this study thought that they were at risk of having LTBI at some 
point in the future; 36% of the study participants were concerned about acquiring LTBI with 
MDR-TB strains; 48% thought of LTBI as a serious health condition; but 43% of HCWs did 
not want to receive treatment for LTBI because they believed that they would be exposed to 
TB again (Table 8). 
Table 8. Health care Worker Beliefs about Latent Tuberculosis Infection and Tuberculosis IC 
(N=240) 
Characteristic 
N
o 
Ch
an
ce
 
(1
), 
no
. (
%
) 
Li
tt
le
 C
ha
nc
e 
(2
), 
no
. (
%
) 
N
o 
O
pi
ni
on
 
(3
), 
no
. (
%
) 
So
m
e 
Ch
an
ce
 
(4
), 
no
. (
%
) 
V
er
y 
G
oo
d 
Ch
an
ce
 
 
 
 
Perceived Susceptibility 
Have LTBI now 48 (20.0) 71 (29.6) 11 (4.6) 72 (30.0) 38 (15.8) 
Will test positive for LTBI 
in the future 
22 (9.2) 65 (27.1) 25 (10.4) 99 (41.3) 29 (12.1) 
Will be diagnosed with TB 35 (14.6) 75 (31.3) 14 (5.8) 104 (43.3) 12 (5.0) 
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in the future 
Characteristic 
St
ro
ng
ly
 A
gr
ee
 
(1
), 
no
. (
%
) 
A
gr
ee
 
(1
), 
no
. (
%
) 
N
o 
O
pi
ni
on
 
(1
), 
no
. (
%
) 
D
isa
gr
ee
 
(1
), 
no
. (
%
) 
St
ro
ng
ly
 D
isa
gr
ee
 
(1
), 
no
. (
%
) 
Perceived Severity 
Worry about acquiring 
LTBI 48 (20.0) 84 (35.0) 43 (17.9) 49 (20.4) 16 (6.7) 
Worry about acquiring TB 
disease 30 (12.5) 62 (25.8) 54 (22.5) 68 (28.3) 26 (10.8) 
Worry about acquiring 
LTBI with MDR-TB strains 16 (6.7) 70 (29.7) 64 (26.7) 63 (26.3) 27 (11.3) 
Latent TB infection is very 
serious 30 (12.5) 87 (36.25) 39 (16.3) 70 (29.2) 14 (5.8) 
Perceived Benefits 
IC measures prevent 
nosocomial TB 
transmission 
86 (35.8) 102 (42.5) 29 (12.1) 21 (8.75) 2 (0.8) 
UV is an effective IC 48 (20) 119 (49.6) 54 (22.5) 12 (5) 7 (2.9) 
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measure 
Respirator protects HCW 
from TB exposure 
116 (48.3) 94 (39.2) 22 (9.2) 5 (2.1) 3 (1.3) 
Respirator protects HCW 
from MDR-TB  exposure 
89 (37.1) 109 (45.4) 36 (15) 5 (2.1) 1 (0.4) 
It is important for 
Georgian HCWs to be 
tested for latent TB 
infection 
100 (41.7) 106 (44.2) 23 (9.6) 9 (3.8) 2 (0.8) 
It is important to test 
contacts of patients with 
TB (family, friends) for 
latent TB infection. 
130 (54.2) 86 (35.8) 15 (6.3) 5 (2.1) 4 (1.7) 
It is important to test 
children who have been 
exposed to TB for latent TB 
infection. 
147 (61.3) 74 (30.8) 16 (6.7) 0 (0.0) 3 (1.3) 
It is important to test 
individuals with 
103 (42.9) 92 (38.3) 38 (15.8) 5 (2.1) 2 (0.8) 
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compromised immune 
systems for latent TB 
infection. 
Perceived Barriers 
UV lights can harm HCWs 31 (12.9) 70 (29.2) 57 (23.8) 73 (30.5) 9 (3.8) 
If I tested positive for 
LTBI, I should not be 
treated because I will be 
exposed again in the future 
33 (13.8) 
 
 
70 (29.2) 
 
 
50 (20.8) 
 
 
69 (28.8) 
 
 
18 (7.5) 
If I tested positive for 
LTBI, I should not be 
treated because probably I 
have drug-resistant TB 
strains 
23 (9.6) 
 
43 (17.9) 
 
 
58 (24.2) 
 
 
93 (38.8) 
 
 
23 (9.6) 
Risks of treating LTBI 
outweigh benefits to 
treating LTBI 
35 (14.6) 
 
70 (29.2) 
 
 
84 (35.0) 
 
 
48 20.0) 
 
 
3 (1.3) 
NOTE. HCW, health care worker; LTBI, latent tuberculosis infection; TB, tuberculosis; 
MDR-TB, multidrug-resistant tuberculosis; IC, IC; UV, ultraviolet. 
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 TB IC Related Behavior or Willingness to Exhibit TB IC-related Behavior 
 
 
A total of 78% of HCWs from the NTP and only 36% of HCWs from the PHCs reported 
frequent use of respirators when they were around patients who were at risk for or who had 
active TB. TB IC–related behavior and willingness to implement TB IC–related behavioral 
change are outlined in Table 9. 
54 
 
Table 9. Tuberculosis IC Related Behavior or Willingness to Exhibit Tuberculosis IC Related 
Behavior (N=240) 
Characteristic No. (%) 
Respirator Use: How often do you wear a respirator when around patients 
who are at risk for or who have active TB? 
 
Frequent 144 (60.0) 
Sometimes 49 (20.4) 
Never 29 (12.1) 
Missing 18 (7.5) 
UV light Use: I do not want to work in an area where UV lights are used.  
Agree 90(37.5) 
No Opinion 53(22.1) 
Disagree 97(40.4) 
LTBI Screening: Would you be willing to be tested each year for latent TB 
infection? 
 
Yes 125 (52.1) 
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No 59 (24.6) 
Undecided 45 (18.8) 
Missing 11(4.6) 
LTBI treatment: If tested positive for latent TB infection, I should be 
treated.  
 
Agree 116 (48.3) 
No Opinion 40 (16.7) 
Disagree 84 (35.0) 
NOTE. TB, tuberculosis; IC, IC; UV, ultraviolet; LTBI, latent tuberculosis infection. 
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Predictors of HCW Knowledge about TB 
 
 
In our multivariate analysis, physicians were more likely to know symptoms suggestive of TB 
disease (aOR, 1.7; 95% CI, 1.0–2.9), TB diagnostic methods (aOR, 1.9; 95% CI, 1.1–3.1), high-
risk groups for TB disease (aOR, 2.3; 95% CI, 1.3–4.0), and LTBI treatment rationale (aOR, 
1.5; 95% CI, 1.0–2.5) than nurses (Table 4). HCWs who worked primarily with TB patients 
were more likely to know about the risk of LTBI progression to TB disease (aOR, 3.2; 95% 
CI, 1.6–6.4), highrisk groups for TB disease (aOR, 2.2; 95% CI, 1.0–4.8), LTBI treatment 
rationale (aOR, 2.3; 95% CI, 1.2–4.5), and LTBI treatment regimen (aOR, 4.2; 95% CI, 1.6–
11.1) than those who did not work with TB patients (Table 10). 
Table 10. Multivariate analysis for predictors of HCWs Tuberculosis Knowledge (N=240) 
Characteristic 
Knowledge Outcomes a and Predictors 
LT
BI
 
Ch
ar
ac
te
ri
st
ic
s, 
aO
R 
(9
5%
 C
I)
 
 Ri
sk
 o
f L
TB
I 
Pr
og
re
ss
 to
 T
B,
 
aO
R 
(9
5%
 C
I)
 
 H
ig
h-
Ri
sk
 g
ro
up
s 
fo
r T
B,
  
aO
R 
(9
5%
 C
I)
 
 TB
 S
ym
pt
om
s, 
aO
R 
(9
5%
 C
I)
 
 TB
 D
ia
gn
os
is,
 
aO
R 
(9
5%
 C
I)
 
 LT
BI
 T
re
at
m
en
t 
Ra
tio
na
l, 
 a
O
R 
(9
5%
 C
I)
 
 LT
BI
 T
re
at
m
en
t 
Re
gi
m
en
,  
aO
R 
(9
5%
 C
I)
 
 
Male vs. 
Female 
1.4 
(0.4, 5.5) 
9.3 c 
(1.9, 44.9) 
1.7 
(0.5, 6.0) 
0.6 
(0.2, 2.5) 
1.6 
(0.5, 5.4) 
1.3 
(0.4, 4.40) 
3.0 
(0.4, 25,8) 
Age, y (60 < vs. 
52 – 60 vs. 
1.3 
(0.8, 2.0) 
0.9 
(0.6, 1.3) 
1.2 
(0.8, 1.8) 
1.5 
(0.9, 2.5) 
1.2 
(0.8, 1.8) 
1.7 c 
(1.1, 2.6) 
1.1 
(0.6, 1.9) 
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45 – 51 vs. 
36 – 44 vs. 
< 35) 
Occupation  
(Physician vs. 
Nurse vs. Other) d 
1.6 
(1.0, 2.6) 
1.4 
(0.8, 2.3) 
2.3 c 
(1.3, 4.0) 
1.7 c 
(1.0, 2.9) 
1.9 c 
(1.1, 3.1) 
1.5 c 
(1.0, 2.5) 
0.6 
(0.3, 1.1) 
Works with TB 
patients vs. does 
not work with TB 
patients 
1.6 
(0.8, 3.2) 
3.2 c 
(1.6, 6.4) 
2.2 c 
(1.0 4.8) 
1.6 
(0.8, 3.3) 
1.4 
(0.7, 2.8) 
2.3 c 
(1.2, 4.5) 
4.2 c 
(1.6, 11.1) 
Length of 
Employment, y 
(35 ≤  vs. 
21 - 34 vs. 
6 - 20 vs. 
≤ 5) d 
0.7 
(0.4, 1.2) 
0.7 
(0.4, 1.3) 
0.9 
(0.5, 1.9) 
0.6 
(0.3, 1.3) 
0.8 
(0.5, 1.5) 
0.5 
(0.2, 0.9) 
0.7 
(0.3, 1.7) 
NOTE. TB knowledge variables were coded as correct versus incorrect answers. 
aOR, adjusted odds ratio; CI, confidence interval; HCW, health care worker; TB, 
tuberculosis; LTBI, latent tuberculosis infection; a Binary logistic regression was used; c 
Statistically significant effect. 
d Ordinal variables. 
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Association between HCW TB Knowledge and Beliefs 
 
 
HCWs who knew the risk of progression from LTBI to TB disease (P < .03) and the high-risk 
groups for TB disease (P< .01) were more likely to worry about acquiring LTBI with drug-
resistant strains than HCWs who did not have this knowledge. HCWs who knew LTBI 
treatment rationale (P< .01) and TB diagnostics (P< .05) were more likely to think that 
screening of TB contacts for LTBI is important than those HCWs who did not demonstrate 
this knowledge. HCWs who knew LTBI characteristics (P< .04), LTBI treatment rationale (P 
<.01), and TB diagnostics (P< .01) more likely felt that immunocompromised individuals 
should be screened for LTBI than those who did not have this knowledge. Only those HCWs 
who knew LTBI characteristics (P< .01) perceived LTBI as a serious infection. As expected, 
HCWs, who worked primarily with TB patients considered themselves more susceptible to 
LTBI than HCWs, who did not (P <.01). 
 
Predictors of TB IC–Related Behaviors 
 
 
HCWs who indicated that they worried about becoming infected with drug-resistant TB 
(aOR, 1.7; 95% CI, 1.29–2.24), HCWs who thought it was important to screen TB contacts 
(aOR, 3.1; 95% CI, 1.25–7.77), and HCWs who were physicians (aOR, 1.6; 95% CI, 1.04–
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2.42) were more likely to be willing to undergo annual screening for LTBI (Table 8). HCWs 
were more likely to refuse treatment for LTBI if they worked in TB facilities (inpatient TB 
facility: aOR 0.3; 95% CI, 0.12–0.68; outpatient TB facility: aOR, 0.2; 95% CI, 0.10–0.35), and 
they perceived a high personal risk of TB reinfection (aOR, 0.5; 95% CI, 0.36–0.64). Those 
who thought that LTBI was a potentially serious health condition were more willing to be 
treated for LTBI (aOR, 2.0; 95% CI, 1.48–2.60) (Table 8). Availability of respirators in HCFs 
was the only significant predictor of routine use of respirators (aOR, 5.1; 95% CI, 3.50–7.30). 
In multivariate analysis, employment in a TB outpatient facility (aOR, 3.1; 95% CI, 1.37–
6.96), perceived susceptibility to LTBI in the future (aOR, 1.4; 95% CI, 1.02–2.03), and the 
perception that UV germicidal radiation was unlikely to harm HCWs (aOR, 0.4; 95% CI, 
0.24–0.50) were identified as independent predictors of willingness to use UV lights in HCFs 
(Table 11). 
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Table 11. Multivariate Analysis for Predictors of Tuberculosis IC-Related Behaviors (N=240) 
 
 
Characteristic 
IC–Related Behavioral Outcomes and Predictors 
Re
sp
ir
at
or
 U
se
, 
aO
R 
(9
5%
 C
I)
a  
 U
V
 L
ig
ht
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se
 
in
 H
CF
, 
aO
R 
(9
5%
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I)
b  
 LT
BI
 
Sc
re
en
in
g,
 
aO
R 
(9
5%
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I)
a  
 LT
BI
 
Tr
ea
tm
en
t, 
aO
R 
(9
5%
 C
I)
a  
Modifying Factors 
TB inpatient vs. non-TB HCF  1.6 
(0.48, 5.29) 
1.3 
(0.43, 3.61) 
1.7 
(0.72, 4.09) 
0.3 c 
(0.12, 0.68) 
TB outpatient vs. non-TB HCF 1.0 
(0.42, 2.18) 
3.1 c 
(1.37, 6.96) 
0.6 
(0.30, 1.17) 
0.2 c 
(0.10, 0.35) 
Occupation d 
 
  1.6 c 
(1.04, 2.42) 
0.7 
(0.42, 1.06) 
Respirator availability d 
 
5.1c 
(3.50, 7.30) 
   
Perceived Threat 
Will test positive for LTBI in the 
future 
 1.4 c 
(1.02, 2.03) 
  
Worry about acquiring LTBI with 
MDR-TB strains 
1.4 
(0.97, 1.97) 
 1.7 c 
(1.29, 2.24) 
 
LTBI is very serious    2.0 c 
(1.48, 2.60) 
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Perceived Benefits 
UV light is an effective TB IC 
measure 
 1.6 
(0.69, 3.46) 
  
It is important to test TB contacts for 
LTBI 
  3.1 c 
(1.25, 7.77) 
 
Perceived barriers  
UV lights can harm HCWs  0.4 c 
(0.24, 0.50) 
  
If I tested positive for LTBI, I should 
not be treated because I will be 
exposed again in the future 
   0.5 c 
(0.36, 0.64) 
NOTE. Occupation was coded as “physician” or “nurse” or “other.” Respirator availability 
was coded as “always,” “most of the time,” “sometimes,” “rare,” or “never.” Respiratory use 
was coded as “frequent,” “sometimes,” or “never.” UV light use in HCF, LTBI screening, and 
LTBI treatment were coded as “yes,” “undecided,” or “no.” aOR, adjusted odds ratio; CI, 
confidence interval; UV, ultraviolet; HCF, health care facility; TB, tuberculosis; LTBI, latent 
tuberculosis infection; MDR-TB, multidrug-resistant tuberculosis; IC, Infection Control; 
HCW, health care worker;  an Ordinal logistic regression was used; b Polytomous logistic 
regression was used; c Statistically significant effect; d Ordinal variable. 
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Discussion  
 
We found a high prevalence of LTBI among Georgian HCWs, which was significantly higher 
among HCWs at TB facilities (55% QFT-GIT positive and 68% TST positive) compared to 
HCWs at non-TB HCFs (32% QFT-GIT positive and 54% TST positive). Furthermore, high 
rates of LTBI diagnostic test conversions were found among Georgian HCWs.  The 
conversion rate (a negative test followed by a subsequent positive test) when using the TST 
was 31.2/100 person-years. The conversion rate by QFT-GIT was 23.0/100 person-years.  
This suggests high rates of occupational exposure to and infection with Mycobacterium 
tuberculosis among Georgian HCWs and highlights the need for implementation of effective 
TB infection control measures. In the survey about TB and TB IC related behaviors 
conducted among HCWs from the NTP and PHCs in Georgia, physicians compared to nurses 
were found to have greater knowledge related to TB and TB IC measures. Also, HCWs who 
worked primarily with TB patients were more educated about TB and related IC activities 
compared to HCWs, who did not see TB patients regularly. HCWs knowledgeable about TB 
and TB IC measures were more likely to perceive their susceptibility to TB infection, the 
severity of TB disease, and TB IC intervention benefits and barriers. Moreover, HCWs who 
perceived their susceptibility to TB infection and net benefit of TB IC measures were more 
likely to comply with IC interventions.   
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The high prevalence of LTBI among Georgian is consistent with reports from India 108, Russia 
109, and Vietnam 110 which have not accomplished implementation of infection control 
measures and have reported prevalence of  positive test results between 40-66% for TST and 
QFT-GIT among HCWs.   
There are limited data on LTBI test conversion rated among HCWs in TB endemic countries 
(low and middle-income countries)111. The most striking findings of our study were high 
rates of LTBI test conversion among Georgian HCWs representing probable recent infection 
with M. tuberculosis. Much higher rates of conversion were seen among Georgian HCWs in 
our study of compared to other studies among HCWs in India that reported TST conversion 
rates of 2.7/100 person-years and QFT-GIT conversion rates of 7.7/100 person-years 112.  A 
study of Malaysian HCWs found QFT-GIT conversion rates of 9.9/100 person-years113.  One 
reason for higher rates of conversion in our study Of note, these other studies were of HCWs 
from hospitals not specializing in TB care, whereas in our study, 61% of HCWs worked in 
facilities specializing in TB care. Our findings highlight a high rate of ongoing transmission 
of TB in Georgian HCFs especially TB HCFs, and the urgent need to implement effective TB 
IC measures.  
There are limited data on IGRA performance in the serial testing of HCWs using in LMIC TB 
endemic countries.  Our study of serial TST and IGRA testing in LMIC with high incidence 
of TB evaluates the relationship between epidemiologic factors (age, degree of occupational 
TB exposure, and TB exposure outside health care settings) and risk of LTBI prevalence and 
the LTBI diagnostic tests conversion.  
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Interestingly, in our study frequent occupation TB exposure was associated only with QFT-
GIT positive results at baseline LTBI screening.  Increasing age was associated with both 
positive TST and positive QFT-GIT at baseline.  Other studies have also found a positive 
association between occupational TB exposure and IGRA positivity rates 114.  Of three cross-
sectional studies of IGRAs and TST conducted in high-incidence settings108-110, only one study 
from India evaluated the association between occupational risk factors for both TST and 
IGRA 108. This study found a stronger, but non-significant, association between occupational 
risk factors and IGRA positivity than for TST positivity108. In the systematic review by 
Zwerling et al., among 22 cross-sectional studies of HCWs in low and moderate incidence TB 
countries, TST, QFT-GIT, and TSPOT.TB correlated well with established indicators of 
occupational risk of TB exposure, although no test was more consistently associated with 
these indicators of exposure 114.   
Both in univariate and multivariate analysis, we did not find an association between 
occupational TB exposure and TST conversions.  QFT-GIT conversion was positively 
associated with increasing age per year only, both in univariate and multivariate analysis. 
Interestingly, we also found that HCWs with BCG vaccination scar were less likely to have 
QFT-GIT conversion in multivariate analysis.  A study from Japan of serial testing of HCWs 
with QFT-GIT found that HCWs, who worked in a TB ward were 20 times more likely to 
experience QFT-GIT conversion than those who did not work in a TB ward91. While we did 
not observe a significant association with TB exposure frequency and TST or QFT-GIT test 
conversion, we did find that 16/19 (84%) TST conversions and 19/24 (79%) QFT-GIT 
65 
 
conversions occurred among HCWs working at a TB facility. Our small sample size for serial 
testing: only 46 HCWs were TST negative on baseline testing and only 81 were negative on 
baseline QFT-GIT testing, limited our ability to detect significance.  However, we found 
higher proportion of HCWs with consistently positive QFT-GIT results on both rounds of 
LTBI testing among HCWs with frequent (≥ twice per month) TB exposure at work 
compared to HCWs with rare (< twice per month) occupation TB exposure (48% vs. 38%, 
p<0.001).  
Absence of a true gold standard test for LTBI presents a major challenge for assessing the 
performance of the LTBI diagnostic tests85. Therefore, we investigated epidemiologic factors 
and the agreement between the two LTBI diagnostic tests at baseline and repeated testing. 
We found higher proportion of concordant results of the two diagnostic tests for LTBI among 
HCWs without BCG vaccination scar vs. HCWs with the scar both at baseline (66% vs. 81%, 
p<0.02, n=308) and repeated testing (79% vs. 70%, p<0.27, n=163). It is important to note 
that the difference was significant only at baseline testing.  Moreover, multivariate analysis 
showed that the HCWs with discordant LTBI test results TST positive / QFT-GIT negative 
group, were less likely to report frequent (≥ twice per month) occupational TB exposure and 
were more likely to have BCG vaccination scar found by inspection compared to the HCWs 
with concordant LTBI test results at baseline LTBI screening. Important to note that only 
increasing age was in positive association with discordant LTBI diagnostic test results at 
repeated testing. 
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Based on our study findings we can argue that TST and QFT-GIT performance differs across 
baseline and repeated testing with respect to the well-established indicators of TB exposure 
in the community and at work. Also, the performance of the two tests differs among HCWs 
with BCG vaccination scar compared to HCWs without the scar. The absence of cross-
reactivity with BCG is an advantage of IGRAs over TST111. BCG vaccination was strongly 
associated with the pattern of TST-positive/ QFT-GIT negative test discordance, as has been 
reported by others20, 115-117. Our results support a role for IGRAs in accurately determining TB 
infection status at baseline screening of HCWs in high TB incidence country with high BCG 
vaccination coverage. 
Georgia has been designated by the WHO as a high burden MDR-TB country111. It is 
particularly important to assess nosocomial TB Transmission to HCWs and to strengthen TB 
IC in HCFs in the setting of a highly endemic M/XDR-TB country, as there are no evidence-
based guidelines for treatment of LTBI due to M/XDR-TB contact 118. Moreover, prior to 2012 
patients with infectious TB were diagnosed and treated in specialized inpatient and 
outpatient TB facilities of the NTP, although persons with undiagnosed TB or suspected cases 
of TB might have been seen at non-TB facilities and referred to a specialized TB facility 
later1. Currently, TB care is provided by diverse non-NTP public and private care providers3. 
This transition introduces a significant risk of nosocomial TB transmission in “non-TB” HCFs 
if effective TB infection control measures are not implemented. We found the same 
prevalence of LTBI among Georgian HCWs from non-TB HCFs (32%) as it is estimated in the 
general population of TB endemic countries41. This finding further highlights the importance 
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of preventing nosocomial TB transmission in non-TB HCFs in Georgia. TB IC should become 
part of the national infection control strategy12.  
Evidence supports that knowledge is a facilitator of compliance with interventions9, 119, 120. 
Nurses who work mainly with TB patients should be targeted for the training given their 
lack of knowledge on this topic. Furthermore, Georgian HCWs who work in non-TB HCFs 
need training about TB and TB IC, as persons with undiagnosed TB or suspected cases of TB 
may be seen at these facilities. This is especially true since TB services are currently being 
integrated with PHCs as part of the ongoing health system reforms in Georgia.  
The survey data were analyzed based on the HBM. The model suggests that individuals 
conduct an internal assessment of the net benefits of changing their behavior and decide 
whether or not to act. The model identifies four aspects of this assessment: perceived 
susceptibility to ill-health (risk perception), perceived severity of ill-health, perceived 
benefits of behavior change, and perceived barriers to taking action.95 Consistent with the 
HBM, UV light use is well-accepted by HCWs who believe that they are at risk of TB 
infection, but HCWs who think that UV lights can be harmful leads to their reluctance to 
use UV lights in HCFs. Perceived LTBI threat predicted HCWs’ readiness to receive LTBI 
treatment while concern for re-infection with TB after LTBI treatment predicted HCWs 
refusal to be treated for LTBI. Given the reported high rates of occupational acquisition of TB 
infection, it is not surprising that Georgian HCWs believe that they remain at risk of TB even 
after treatment for LTBI. We also found that respirators are not always available for all 
HCWs, especially in non-TB HCFs. These findings emphasize the need to strengthen IC 
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measures in Georgian HCFs and provide important baseline information for the Georgian 
Ministry of Health, Labor, and Social Affairs that is currently implementing IC interventions 
in HCFs.  
In summary, our study is the first survey of HCWs’ knowledge, beliefs, and behaviors about 
TB IC and LTBI screening and treatment in Georgia. We were able to identify specific 
knowledge gaps and beliefs to be addressed during implementation of TB IC measures in 
Georgian HCFs. Researchers and HCF administrators should pursue the application of 
behavioral science methods to strengthen TB IC measures implementation process.39   Based 
on our survey findings, a targeted campaign is needed to raise HCWs’ awareness about TB 
and about the benefits of TB IC measures to prevent the nosocomial transmission of TB and 
the particular threats of drug-resistant TB in the country Georgia. 
 
Limitations 
 
 
Both, the longitudinal study of the rates and risk factors for LTBI among Georgian HCWs 
and the anonymous survey about the determinants of TB IC-related behaviors among 
Georgina HCWs, had several limitations. In the study of the rates and risk factors for LTBI 
among HCWs in Georgia only 45 participants were included from outside of the capital city, 
Tbilisi. Although TB services’ infrastructure, level of TB IC measures implementation, and 
HCWs compliance to the existing TB IC measures are about the same across the Georgian 
HCFs, one third of the notified TB patients in Georgia undergo TB diagnosis and initial phase 
69 
 
of TB treatment in HCFs in Tbilisi. Therefore, the LTBI prevalence and incidence rates 
among Georgian HCWs might be slightly overestimated in this study. Furthermore, because 
of the high prevalence of LTBI, the number of uninfected HCWs who were at risk for LTBI 
test conversions was modest (81 were at risk for QFT-GIT conversion and 46 for TST 
conversion).  HCWs are not routinely tested for LTBI in Georgia (and the vast majority of 
LMICs) so there may have been selection or volunteer bias on HCWs, who chose to 
participate in our study.  Only 53% (163/308) of the HCWs enrolled in the study had 
repeated LTBI tests performed, which could have introduced bias with respect to conversion 
rates and risk factors.  Finally, repeat testing occurred at different time intervals but this was 
clearly documented, so we were able to calculate conversion rates over time. 
One limitation of the anonymous survey is that TB IC related behaviors were self-reported 
rather than observed. For instance, respirator use was measured by HCWs’ responses to 
anonymous questions, rather than by observations of this behavior by the study team. 
Another limitation of our study is that convenience sampling was used, and 19% of those 
who were approached did not agree to complete the survey. Most of the non-responders (53 
out of 58 HCWs) were nurses from the NTP, potentially introducing selection bias. Physician 
to nurse ratio in TB services and PHCs is about one to one in Georgia. Therefore, we 
expected the nearly equal proportion of nurses and physicians in our study population.  
Physicians comprised 48% of our population, and nurses comprised 40%, so our study 
slightly overrepresented physicians compared to nurses. A major strength of the anonymous 
survey  is that it included various types of HCWs from across the whole country.  
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Conclusions  
1. We found a high prevalence of LTBI among Georgian HCWs. 
i. LTBI prevalence was significantly higher among HCWs at TB facilities 
compared to HCWs at non-TB HCFs. 
 
2. We found high rates of LTBI diagnostic test conversions among Georgian HCWs.   
i. The majority (80%) of TST and QFT-GIT  conversions occurred among HCWs 
working at TB facilities 
 
3. The performance of TST and QFT-GIT varied with respect to indicators of TB 
exposure both at baseline and at repeated testing.  
 
i. Indicators of occupational TB exposure - frequent contact with TB patients at 
work, was positively associated with only QFT-GIT positive results at baseline; 
ii. Increasing age was associated with both positive TST and positive QFT-GIT at 
baseline;  
iii. We did not find association between occupational TB exposure and TST or 
QFT-GIT conversions; 
Note: Our small sample size for serial testing: only 46 HCWs were TST 
negative on baseline testing and only 81 were negative on baseline 
QFT-GIT testing, limited our ability to detect significance.   
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iv. Increasing age was positively associated with QFT-GIT conversion, and HCWs 
with BCG vaccination scar were less likely to experience QFT-GIT conversion; 
 
v. We found higher proportion of HCWs with consistently positive QFT-GIT 
results on both rounds of LTBI testing among HCWs with frequent (≥ twice 
per month) TB exposure at work compared to HCWs with rare (< twice per 
month) occupation TB exposure. 
Note: As opposed to the small sample size for the detection of risk 
factors associated with QFT-GIT and TST conversions (concluson 3-iii), 
propotions of consitantly positive QFT-GIT test across the occupation 
TB exposure friequency were compared among 163 HCWs, who 
underwent serial testing for LTBI. Possibly, the larger samle size 
alowed us to detect statistically significant association between 
conistantly posittive QFT-GIT and the occupation TB exposure.  
 
4. TST and QFT-GIT performance differs among HCWs with BCG vaccination scar 
compared to HCWs without the scar at baseline screening of HCWs 
i. We found higher proportion of concordant results of the two diagnostic tests 
for LTBI among HCWs without BCG vaccination scar vs. HCWs with the scar 
both at baseline; 
72 
 
ii. HCWs with discordant LTBI test results TST positive / QFT-GIT negative 
group, were less likely to report frequent (≥ twice per month) occupational TB 
exposure and were more likely to have BCG vaccination scar found by 
inspection compared to the HCWs with concordant LTBI test results at 
baseline LTBI screening. Only increasing age was in positive association with 
discordant LTBI diagnostic test results at repeated testing. 
 
5. We found that moderate knowledge of TB and TB IC among Georgian HCWs  
i. Physicians compared to nurses were found to have greater knowledge related 
to TB and TB IC measures.  
ii. HCWs, who worked primarily with TB patients, were more educated about TB 
and related IC activities compared to HCWs, who did not see TB patients 
regularly. 
 
6. Consistent with the Health Belief Model,  
i. HCWs knowledgeable about TB and TB IC measures were more likely to 
perceive their susceptibility to TB infection, the severity of TB disease, and 
TB IC intervention benefits and barriers.   
ii. HCWs, who perceived their susceptibility to TB infection and net benefit 
of TB IC measures, were more likely to comply with IC interventions.   
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 UV light use is well-accepted by HCWs, who believe that they are 
at risk of TB infection, but HCWs who think that UV lights can be 
harmful leads to their reluctance to use UV lights in HCFs.  
 Perceived LTBI threat predicted HCWs’ readiness to receive LTBI 
treatment while concern for re-infection with TB after LTBI 
treatment predicted HCWs refusal to be treated for LTBI.  
 
7. We found that respirators were not always available for all HCWs, especially in non-
TB HCFs 
 
8. Our study findings suggest a high rate of ongoing transmission of TB in Georgian 
HCFs especially TB HCFs and the urgent need to implement effective TB IC 
measures. 
Note: Prior to 2012 patients with infectious TB were diagnosed and treated in 
specialized inpatient and outpatient TB facilities of the NTP, although persons 
with undiagnosed TB or suspected cases of TB might have been seen at non-TB 
facilities and referred to a specialized TB facility later1. Currently, TB care is 
provided by diverse non-NTP public and private care providers3. This 
transition introduces a high risk of nosocomial TB transmission in non-TB 
HCFs too. Findings of our study about the same prevalence of LTBI among 
Georgian HCWs from non-TB HCFs (32%) as it is estimated in general 
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population of TB endemic countries41 further highlights  importance  of 
preventing nosocomial TB transmission in non-TB HCFs in Georgia 
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Practical Recommendations 
 
1. Based on our study findings that there are high rates of LTBI prevalence and 
incidence among Georgina HCWs, TB IC measures should urgently be implemented 
in Georgian HCFs.  
 
2. Considering ongoing transition of TB services from the NTP specialized TB facilities 
to non-NTP public and private TB facilities, TB IC strategy should become integral 
part of the National IC strategy in Georgia12. 
 
3. The set of TB infection control measures should be monitored and evaluated12  
i. Introduce screening of HCWs at baseline and five years after TB IC measures 
implementation to assess change in nosocomial TB transmission rates12 
 
ii. Use QFT-GIT for screening of HCWs to monitor TB IC measures 
implementation in Georgian HCFs.  
Note: Although in resource-limited, highly endemic TB countries, resources 
would likely be better spent on strengthening TB IC measures than on the 
extra cost of IGRA screening, our study findings showed that none of the well-
established indicators of TB occupational exposure was associated with TST 
positive test results either at baseline or repeated testing. Furthermore, we 
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found that rare occupational TB exposure and presence of BCG vaccination 
scar was strongly associated with TST positive/QFT-GIT negative test results at 
baseline. Our results support a role for IGRAs in accurately determining TB 
infection status at baseline screening of HCWs in high TB incidence country 
with high BCG vaccination coverage. 
4. Operational research should be enabled and conducted12  
i. Further evidence from IGRA serial testing studies, including long-term follow 
up data of “converters” is needed, to be able to determine what changes in 
IGRA test values constitute the development of LTBI infection 
 
5. Researchers and HCF administrators should pursue the application of behavioral 
science methods to strengthen TB IC measures implementation process39 
 
6. Based on our survey findings, a targeted campaign should be introduced to raise 
HCWs’ awareness about TB and about the benefits of TB IC measures to prevent the 
nosocomial transmission of TB and the particular threats of drug-resistant TB in the 
country Georgia. 
i. Nurses who work mainly with TB patients should be targeted for the 
training given their lack of knowledge on this topic 
ii. Georgian HCWs, who work in non-TB HCFs, need training about TB and 
TB IC, as persons with undiagnosed TB or suspected cases of TB may be 
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seen at these facilities. This is especially true since TB services are 
currently being integrated with PHCs as part of the ongoing health system 
reforms in Georgia 
7. Include module on TB transmission and TB IC in the state Continues Medical 
Educating program  
8. Introduce LTBI preventive therapy among HCWs only after documented decline in 
nosocomial TB transmission and  decrease of TB prevalence < 100/100,000 population 
per year47 
Note: As per the latest WHO guidelines on the management of latent 
tuberculosis infection47 systematic testing and treatment of LTBI should be 
considered for HCWs from high-income or upper middle-income countries 
with an estimated TB incidence rate of less than 100 per 100 000 population. 
The Panel judged that these countries are most likely to benefit from 
systematic testing and treatment of LTBI for HCWs due to their current TB 
epidemiology and resource availability. Resource-limited countries and other 
middle-income countries that do not belong to the above category should 
implement treatment of LTBI among people living with HIV and child 
contacts below 5 years of age. 
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Appendix 1. Questionnaire 
 
Date _____/_____/____ 
 
A. Patient Identification Code  -         
 
Health Care Facility ____________________________ 
 Medical School 
 Non TB Health Facility  
 TB Outpatient Clinic 
 TB Inpatient Clinic 
 Other 
 
Location of the Facility _________________________ 
 Tbilisi 
 Other 
  
Name  
Last___________________________ First____________________  
 
Contact Phone Number: _________________________________ 
 
 
 
B. Demographics 
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 Date of birth ____/___/________ (dd-mm-year)                    
 
Gender  
 Male                          
 Female 
 
Country of birth  
 Georgia 
 Other (specify)   
 
Year arrived in Georgia __________________ 
 
Ethnicity 
 Georgian    
 Other (Specify) _________________ 
 
Education 
 Graduate 
 Undergraduate  
 High School 
 Did not finish high school 
 
Profession 
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 Physician               
 Nurse                  
 Lab Worker          
 Outreach worker  
 Medical Student             
 Other ___________________ 
 
C. Vaccination 
Prior History of BCG Vaccination   
Yes                                   (If yes, how many total vaccinations? ___ )  
 No    
 Don’t Know 
 
BCG Scar  
Yes      
 No   
 
Baseline LTBI Testing 
 
Medical History  
Last TST    
Yes   
(If yes, year of the last TST______; result of the last TST  Negative  Positive) 
 No                                                                                     
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 Don’t Know 
 
Known Household Tuberculosis Contact  
Yes                                 
(If yes,  immediate;  extended)  
 No   
 Don’t Know 
 
Known Tuberculosis Contact outside Work and Household 
Yes 
(If yes,  immediate;  extended)                                      
 No   
 Don’t Know 
 
Prior History of TB Disease  
 Yes                                    (If yes, Year? ___________________) 
 No               
 
Did you begin TB treatment?       Yes    No    Don’t Know  
               
Did you complete TB treatment? Yes    No    Don’t Know  
                                                                     
Were you declared cured of TB?  Yes    No    Don’t Know 
Employment History 
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Job Title:  ____________________________   Years in Current Position:  ________________ 
 
Occupation  
 Administrative and Technical Staff   
 Physician               
 Nurse                  
 Lab Worker          
 Outreach worker  
 Medical Student             
 Other  
How much exposure to TB do you have at work?  
 Daily  
 Frequent  
 Rare 
 Very Rare 
 
Prior Positions: ________________________     
 
Years in Prior Position:  _______________ 
 
Total number of years in Health-care (including medical training) _____________ 
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Appendix 2.  Data Collection Form 
 
Patient Identification Code   -         
 
Name: First, Last __________________________________________  
 
I round:  
 
Tuberculin Skin Test (TST)         / Normal Value: < 10 mm / 
               
Date TST placed: ____/____/_____     Location placed:  Left Forearm  Right Forearm 
  
Date TST read: ____/____/_____ 
 
Result: ______ mm of induration   (If no induration, mark “0”) 
  
QuantiFERON-TB Gold in Tube Test         /Normal Value: < 0.35 IU /ml /            
 
Date Blood Drown: ____/____/_____ 
 
Result: ______IU/ml 
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II round:  
 
Tuberculin Skin Test (TST)         / Normal Value: < 10 mm / 
               
Date TST placed: ____/____/_____     Location placed:  Left Forearm  Right Forearm 
  
Date TST read: ____/____/_____ 
 
Result: ______ mm of induration   (If no induration, mark “0”) 
 
QuantiFERON-TB Gold in Tube Test         /Normal Value: < 0.35 IU /ml / 
            
Date Blood Drown: ____/____/_____ 
 
Result: ______IU/ml 
 
   
QuantiFERON-TB Gold in Tube Test  (QFT-GIT)       /Normal Value: < 0.35 IU /ml / 
 
Date Blood Drown: ____/____/_____ 
 
Result: ______IU/ml 
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 Additional Comments: -----------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
----------------------------------------------------- 
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 Appendix 3. Healthcare Provider Survey about Latent Tuberculosis Infection  
 
Thank you for taking the time to complete this survey about your experiences with 
Tuberculosis (TB).  This is an anonymous survey.  Neither your name (nor any other 
identifying information) will be collected or linked to your responses on this survey, so 
please respond to each question as accurately and honestly as possible. 
 
First, please, answer the following questions about your exposure to TB 
 
1.  Which city do you work in? (Check only one answer) 
    _____ Tbilisi          
    _____ Abastumani 
    _____ Batumi 
    _____ Kutaisi 
    _____ Poti 
    _____ Zugadidi 
    _____ Other  
 
2. Which of the following health facility do you work at? (Check only one answer) 
            _____ Medical School 
 _____ Non TB Health Facility 
 _____ TB Outpatient Clinic  
 _____ TB Inpatient Clinic  
            _____ Other  
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[PLEASE CONTINUE TO THE NEXT PAGE] 
 
3.  Do you work primarily with tuberculosis patients? 
  _____ Yes 
             _____ No  
 
Please answer the following questions about TB transmission, infection and treatment.   
 
4.  TB organisms are most commonly transmitted from person-to-person in which of the 
following ways? (Check only one answer). 
 _____ Blood and bodily fluids 
 _____ Aerosol 
 _____ Food 
 _____ Shared objects  
 
5.  Which of the following groups are among those at an increased risk for developing active 
TB? (Check all that apply). 
 _____ Young children  
_____ Healthcare workers 
 _____ HIV-infected individuals 
 _____ Individuals with heart disease   
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[PLEASE CONTINUE TO THE NEXT PAGE] 
 
6.  Common symptoms of active TB disease include all of the following EXCEPT:  (Check all 
that apply). 
 _____ Cough 
 _____ Night Sweats 
 _____ Weight loss 
 _____ Diarrhea  
 _____ Vomiting  
 
7.  Individuals with latent TB infection have which of the following characteristics: (Check 
all that apply). 
 
 _____ They are asymptomatic 
 _____ They are at risk of progressing to active TB disease 
 _____ They are infectious and can spread tuberculosis to others 
 _____ They will likely have a skin test or blood test result indicating latent TB 
infection 
8.  Generally, what percentage of people who have latent TB infection and a normal immune 
system will go on to develop active TB at some point in their lives? (Check only one answer). 
 
 _____ <1% 
 _____ 5-10% 
 _____ 30-50% 
 _____ >80% 
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[PLEASE CONTINUE TO THE NEXT PAGE] 
 
9.  Which of the following tests is required to diagnose active pulmonary TB? (Check all that 
apply). 
 _____ TB skin test  
_____ TB blood tests  
_____ Chest X-ray 
_____AFB smear and culture of sputum 
 
10.  The primary rationale for treating latent TB infection is to: (Check only one answer) 
 _____ Reduce the risk that a person with latent TB can infect others 
 _____ Reduce the risk that TB infection will progress to disease 
 _____ Reduce the risk that a person with latent TB will be infected again in the future 
 _____ Reduce the risk that a person will develop multidrug-resistant TB 
 
11.  Which of the following regimens is the preferred method for the treatment of latent TB 
infection? (Check only one answer). 
 _____ Isoniazid for 6-9 months 
 _____ Rifampin and Pyrazinamide for 2 months 
 _____ Rifampin for 4 months 
 _____ Ofloxacin for 3 months 
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[PLEASE CONTINUE TO THE NEXT PAGE] 
12.  The TB skin test can cause tuberculosis infection. 
 _____ True 
 _____ False 
 _____ I don’t know 
 
Next, we are interested in your thoughts about latent TB infection.  For the following 
questions, please indicate the degree to which you agree or disagree with the below 
statements by circling your answer.   
 
 Strongly  
Agree 
(1) 
Agree 
 
(2) 
No 
Opinion 
(3) 
Disagree 
 
(4) 
Strongly 
Disagree 
(5) 
13.  I worry about acquiring latent TB 
infection.   
 
1 
 
2 
 
 
3 
 
4 
 
5 
14.  I worry about acquiring active TB 
infection. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
15.  I worry about acquiring latent TB 
infection with multi-drug resistant TB. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
16.  Latent TB infection is very serious.  
1 
 
2 
 
3 
 
4 
 
5 
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 [PLEASE CONTINUE TO THE NEXT PAGE] 
Please indicate the degree to which you think the following situations may occur by circling 
your answer.   
 
 No  
Chance 
(1) 
Little  
Chance 
(2) 
Some  
Chance 
(3) 
Very Good 
Chance 
(4) 
17.  I would test positive for latent TB 
infection if I were tested today. 
 
1 
 
2 
 
 
3 
 
4 
18. At some point in the future, I will test 
positive for latent TB infection. 
 
1 
 
2 
 
 
3 
 
4 
19. At some point in the future, I will test 
positive for active TB. 
 
1 
 
2 
 
 
3 
 
4 
 
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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Next, we are interested in your thoughts about preventing the transmission of TB infection.  
For the following questions, please indicate the degree to which you agree or disagree with 
the below statements by circling your answer. 
 Strongly  
Agree 
(1) 
Agree 
 
(2) 
No 
Opinion 
(3) 
Disagree 
 
(4) 
Strongly 
Disagree 
(5) 
20.  Implementation of effective TB 
infection control measures can prevent 
transmission of TB in hospitals. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
21.  UV light is an effective TB infection 
control measure. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
22.  UV lights can harm health care 
workers. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
23.  I do not want to work in an area 
where UV lights are used 
 
1 
 
2 
 
 
3 
 
4 
 
5 
24.  Using respirators to prevent exposing 
healthcare workers to TB is important. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
25.  Using  surgical masks by TB patients 
to prevent TB transmission is important 
 
1 
 
2 
 
 
3 
 
4 
 
5 
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26.  Using respirators to prevent the 
transmission of multi-drug resistant TB is 
important. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
27.  Using TB isolation rooms with those 
who have active TB in order to prevent 
transmission is important. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
28.  Instruction for those at high risk for 
or who have active TB in respiratory 
hygiene/cough etiquette is important. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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Please answer the next additional questions about your experience with infection control 
practices for latent TB infection.   
 
29.  How frequently are respirators available to you? (Check only one answer). 
 _____ Always 
 _____ Most of the time 
 _____Sometimes 
 _____ Rarely 
 _____ Never 
 
30.  How often do you wear a respirator when around patients who are at risk for or who 
have active TB or TB disease?  (Check only one answer). 
 _____ Always → Skip to question 32 
 _____ Most of the time → Go to the next question 
 _____Sometimes → Go to the next question 
 _____ Rarely → Go to the next question 
 _____ Never → Go to the next question 
31.  What is the primary reason why you do not wear a respirator all of the time? (Check 
only one answer). 
 _____ Respirators are not available to me when I need them. 
 _____ I have not been instructed to wear a respirator. 
_____ I do not believe masks are effective at preventing TB transmission. 
 _____ Respirators are uncomfortable. 
 _____ Other (please specify: _______________________________________) 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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 32.  Are TB isolation rooms or wards used for patients in your facility? (Check only one 
answer). 
 _____ Yes  
 _____ No 
 _____ I don’t know 
Next, we are interested in your thoughts about testing for latent TB infection.  For the 
following questions, please indicate the degree to which you agree or disagree with the 
below statements by circling your answer. 
 
 Strongly  
Agree 
(1) 
Agree 
 
(2) 
No 
Opinion 
(3) 
Disagree 
 
(4) 
Strongly 
Disagree 
(5) 
33.  It is important for Georgian 
healthcare workers to be tested for latent 
TB infection. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
34.  It is important to test contacts of 
patients with active TB (family, friends) 
for latent TB infection.  
 
1 
 
2 
 
 
3 
 
4 
 
5 
35.  It is important to test children who 
have been exposed to TB for latent TB 
infection. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
36.  It is important to test individuals with 
compromised immune systems for latent 
TB infection. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
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Please answer the next additional questions about testing for latent TB infection.   
 
37.  Would you be willing to be tested each year for latent TB infection? (Check only one 
answer). 
 _____ Yes → Go to the next question  
 _____ No → Skip to question 39 
 _____ Undecided → Go to the next question 
38.  Which of the following latent TB infection testing methods would you prefer? (Check 
only one answer). 
 
 _____ The skin test 
 _____ The blood test 
 _____ Either (I don’t have a preference) 
 
 
 
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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We are also interested in your thoughts about treating latent TB infection.  For the following 
questions, please indicate the degree to which you agree or disagree with the below 
statements by circling your answer.   
 
 Strongly  
Agree 
(1) 
Agree 
 
(2) 
No 
Opinion 
(3) 
Disagree 
 
(4) 
Strongly 
Disagree 
(5) 
39.  If I tested positive for latent TB 
infection, I should be treated. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
40.  If I tested positive for latent TB 
infection, I should not be treated because I 
will be exposed again in the future. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
41.  If I tested positive for latent TB 
infection, I should not be treated because 
the TB I have is probably resistant to the 
medications. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
42.  The benefits to treating latent TB 
infection outweigh the risks of treating 
latent TB infection. 
 
1 
 
2 
 
 
3 
 
4 
 
5 
 
Finally, we would like to know a little more about you.  Please answer the below questions 
as honestly and accurately as possible.   
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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 43.  How old are you (in years)?      
I am ________ years old. 
 
44.  What is your biological sex? (Check one):  
_____ Male   
_____ Female  
 
45.  Approximately how many years have you worked in healthcare full-time? 
 _____ years 
 
46.  What is your primary job title? (Check only one answer): 
_____ Administrative and Technical Staff   
_____ Physician               
_____ Nurse                 
_____ Laboratory Worker          
_____ Outreach worker  
_____ Medical Student             
_____ Other  
 
 
 
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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 47.  In what type of patient care are you involved? (Check one): 
_____ I am not involved in patient care directly→ Skip to question 49 
 _____ Primarily inpatient 
 _____ Primarily outpatient 
 _____ Both inpatient and outpatient 
 
48. With which patient population do you primarily work? (Check one): 
 
 _____ Adults 
 _____ Children 
 _____ Both adults and children 
 
49.  Have you had the BCG vaccine? (Check one): 
 _____ Yes  
 _____ No 
 _____ I don’t remember 
 
50.  Have you had a TB skin test before? (Check one): 
 _____Yes → Go to the next question 
 _____ No → Skip to question # 54 
 _____ I don’t remember → Skip to question # 54 
 
[PLEASE CONTINUE TO THE NEXT PAGE] 
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51.  Was the TB skin test positive? (Check one): 
 _____ Yes → Go to the next question 
 _____ No → Skip to #54 
 _____ I don’t remember 
 
52.  Approximately how long ago was the most positive TB skin test?  
 _____ months, _____years ago 
 
53.  Have you been treated for latent TB infection (positive TB skin test) before?  (Check 
one): 
_____ Yes 
 _____ No 
 _____ I don’t remember 
54.  Have you been diagnosed with active TB before? (Check one): 
_____ No→ YOU HAVE COMPLETED THE SURVEY 
 _____ I don’t remember→ YOU HAVE COMPLETED THE SURVEY 
 _____ Yes 
 
55.  Have you been treated for active TB before?  (Check one): 
 _____ Yes 
 _____ No 
 _____ I don’t remember 
 
You have completed the survey.  We appreciate you taking the time to share your thoughts 
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Appendix 4. Methodology for Drawing Blood 
 
1. Clean the skin with alcohol swab and allow drying. 
2. A total of 3 ml of blood will be drawn for the QuantiFERON-TB Gold in Tube (QFT-
3G) test.   
a. The blood may be collected directly into the vacutainer tubes or collected with 
a syringe (without heparin) and transferred into the vacutainer tubes.  
b. Invert each tube several (at least 5) times immediately after collecting the 
blood to mix it with heparin.     
c.  The set of QFT-3G tubes consists of a “Nil Control” gray-topped tube, a blue-
topped tube that contains TB antigens, and an “Positive Control” orange-
topped tube that contains Mitogen.  One (1) ml of blood should be collected 
into each of the QFT-3G tubes (e.g. up to the black line on the side).  Do not 
overfill the tubes.  Leave the QFT-3G connected to the needle for 2 seconds 
after blood stops flowing. 
3. Cover the puncture site with a Band-Aid and confirm that bleeding has stopped. 
4. Shake the blood in the QFT-3G tubes for 5 seconds and place them upright in a tube-
rack.   The QFT-3G tubes must be mixed more vigorously to wash the antigens off the 
tube walls where they were sprayed during the manufacturing process.  After being 
shaken, the QFT-3G tubes should NOT be mixed any further. 
5. Label the tubes with the Subject's number. 
6. Record collection time on the appropriate forms. 
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7. Transport the tubes of blood at room temperature to the lab for further processing.  
The blood should be taken to the lab as soon as possible and definitely within 12 
hours.  The QFT-3G tubes should be transported upright in a tube rack.   
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Appendix 5.  QuantiFERON-TB Gold In-tube 
 
Antigen Storage and Preparation for use  
 
1. QFT-3G tubes containing antigen: 
 
a) A set of QFT-3G tubes is used for each test to be performed.  A set QFT-3G tubes 
consists of a “Nil Control” gray-topped tube, a blue-topped tube that contains TB 
antigens, and an “Positive Control” orange-topped tube that contains Mitogen.   
b) For long-term storage, these tubes should be stored at 2 to 8°C (refrigerated). Prior to 
use the tubes can be kept at room temperature for periods up to 2 weeks.   
 
Stimulation of Blood with Antigens for QFT-3G and Storage of Plasmas 
 
I. Stimulation of blood for QFT-3G assay: 
 
1. Place QFT-3G tubes upright in 37°C incubator (without additional mixing). 
Incubation of QFT-3G tubes should begin as soon as possible after blood 
collection, and must begin within 12 hrs of obtaining blood.   
2. Record time QFT-3G incubation began on the appropriate form. 
3. Incubate the QFT-3G tubes upright at 37°C for 20 to 40 hours.  Record time 
incubation ended on the appropriate form. 
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4. After incubation is completed, centrifuge the tubes in a clinical centrifuge at 1,500 
to 2,200g for 5 minutes at room temperature (22+5°C) to get the cells and debris 
out of the plasma and below the gel plug. 
5. Transfer at least 300 µL of stimulated plasma from each QFT-3G tube to 1.2 ml 
micro-tubes appropriately labeled and positioned as described below (and 
illustrated in Table 1). 
A. Wrap a 3.25 X 3/8 inch label with the subject’s ID number around 3 of the 1.2 
ml micro-tubes.   
*B. Use a black indelible marker to mark the first tube, that will contain the “Nil” 
QFT-3G plasmas. 
C.  Place tube is consecutively numbered boxes labeled with the study name, 
initial date used, and “QFT-3G Plasmas”. 
D. Record the storage position of each plasma on the appropriate form. 
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 Table 1: Storage layout for QFT-3G plasma samples (32 subjects / plate) 
 
 1* 2 3 4* 5 6 7* 8 9 10* 11 12 
A N(1) T(1) M(1) N(9) T(9) M(9) N(17) T(17) M(17) N(25) T(25) M(25) 
B N(2) T(2) M(2) N(10) T(10) M(10) N(18) T(18) M(18) N(26) T(26) M(26) 
C N(3) T(3) M(3) N(11) T(11) M(11) N(19) T(19) M(19) N(27) T(27) M(27) 
D N(4) T(4) M(4) N(12) T(12) M(12) N(2) T(20) M(20) N(28) T(28) M(28) 
E N(5) T(5) M(5) N(13) T(13) M(13) N(2) T(21) M(21) N(29) T(29) M(29) 
F N(6) T(6) M(6) N(14) T(14) M(14) N(2) T(22) M(22) N(30) T(30) M(30) 
G N(7) T(7) M(7) N(15) T(15) M(15) N(2) T(23) M(23) N(31) T(31) M(31) 
H N(8) T(8) M(8) N(16) T(16) M(16) N(2) T(24) M(24) N(32) T(32) M(32) 
 
N = NIL QFT-3G plasma, T= TB antigen stimulated QFT-3G plasma, and M=Mitogen 
stimulated QFT-3G stimulated plasma;  Numbers in parentheses indicate samples from 32 
different patients (1) through (32). Example: N(1) = Nil QFT-3G plasma from first subject's 
blood sample. 
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III. Storage of Plasmas for QFT-3G assay: 
1.  Tubes containing stimulated plasmas should be refrigerated or frozen within 12 hours 
of collection.  Caps should be placed on tubes within 24 hours.  
2.  After capping tubes, place each box of microtubes in a separate Zip Lock bag and store 
for up to 2 weeks at 4° C.  The plasmas should be stored at -70° C for longer periods. The 
freezer should not be frost-free. 
Note: Performing ELISAs prior to refrigeration decrease clot formation in plasmas. 
ELISA Methods for QFT-3G 
Note: QFT-3G ELISA uses the “QuantiFERON-CMI” kit and is for “Nil”, “TB antigen”, and 
“Mitogen” stimulated plasmas collected from the QFT-3G tubes. 
Please be familiar with the current “QuantiFERON-CMI” package insert but follow 
these instructions when performing the QFT-3G ELISAs for this study. 
While QFT-3G ELISA uses different reagents which are specifically for the CMI 
assay, the procedure is similar to the QFT-1G assay.  Differences in the procedure for 
performing the QFT-1G ELISA as compared to QFT-3G ELISA are indicated with an *. 
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1. If not previously done and available,  
*a)  reconstitute the CMI IFN-γ standard by adding 1.5mL of deionised or distilled 
water to the vial.  Mix gently to minimize frothing but ensure complete 
resolubilization.  Record the date the standard was reconstituted on the vial.  
Reconstituted stock CMI IFN-γ Standard may be kept for up to 3 months if stored 
at 2°C to 8°C. 
b)  reconstitute freeze dried Conjugate (to make 100X Concentrate) by adding 0.3mL 
of deionised or distilled water. Ensure complete resolubilization of the Conjugate 
by mix thoroughly but gently to minimize frothing.  Return the Conjugate to 2 to 
8 C as soon as possible.  Reconstituted Conjugate should be used with 3 months. 
c)  dilute 1 part Wash Buffer 20X Concentrate with 19 parts deionised or distilled 
water and mix thoroughly.  Each plate uses about 1 liter of diluted wash buffer.  
Diluted wash buffer should be used within 2 weeks of preparation. 
2. Except for Conjugate (100X Concentrate), other reagents including standards, are 
brought to room temperature before use.    Allow at least 60 min for equilibration. 
*3. Prepare fresh dilutions for IFN-γ standards for each assay.  Use the reconstituted stock 
CMI IFN-γ Standard to produce a dilution series of 3 IFN-γ concentrations as follows: 
a) label 4 microtubes S1 to S4. 
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 b) add 200 µL of Green Diluent to the 3 tubes labeled S2 to S4. 
c) set S4 aside to avoid adding IFN-γ 
d) add 200  µL of the reconstituted stock CMI IFN-γ Standard to the tubes labeled S1 
and S2. 
e) mix S2 thoroughly, change the tip and transfer 200 µL from S2 to S3. 
f)  mix s3 thoroughly.  Do not add IFN-γ to S4. 
4. Vortex plasma samples before performing ELISA. 
5. Record requested information on ELISA worksheet (Appendix 3g including staff, 
reagent lot numbers, test samples, times, and temperatures. 
6.  Dilute the required amount of Conjugate 100X Concentrate in Green Diluent (as 
shown in Table 1).   Add 50 µl of freshly prepared Conjugate to the required wells of 
an ELISA plate using a multichannel pipette.  Use the diluted Conjugate within 30 
minutes of preparation. 
       TABLE 1. CONJUGATE Preparation Table 
# of 
Strips 
Volume of 100 x 
Conjugate 
Volume of Green 
Diluent 
1 5µL 0.5 mL 
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 2 10µL 1.0 mL 
3 15µL 1.5 mL 
4 20µL 2.0 mL 
5 25µL 2.5 mL 
6 30µL 3.0 mL 
7 35µL 3.5 mL 
8 40µL 4.0 mL 
9 45µL 4.5 mL 
10 50µL 5.0 mL 
11 55µL 5.5 mL 
12 60µL 6.0 mL 
 
*7. Use a multichannel pipette to add 50 µl of Mitogen (M) and Nil (N) stimulated plasmas, 
and M. tuberculosis-specific antigen stimulated plasmas (e.g. SA1 through SA8, or SA1b 
to SA8b) from each patient, and diluted standards to the appropriate ELISA wells as 
shown in the worksheet template on page Error! Bookmark not defined..  Add QFT-3G 
Nil, QFT-3G TB, and QFT-3G Mitogen stimulated plasmas in place of SA6, SA7, and 
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 SA8 if available.  Standards should be added last and incubation time begun once they 
are added. 
Note: Pipetting should be done with extreme care to avoid pipette tips becoming blocked 
with cryoprecipitate that may be present in thawed plasmas.  Tip volumes should be 
checked before addition to ELISA wells.  Plasma samples may be cleared of clotted 
material by centrifugation. 
8. Place the lid on the ELISA plate and mix with a microplate shaker for 1 min with 
waveform set at 20 and amplitude set at 6 (not 9 as for blood). 
*9. Incubate plates away from direct sunlight at room temperature (22°C +/- 5°C) for 2 
hours at room temperature (as distinct from 1 hour for the QuantiFERON-TB ELISA) 
10. Wash the ELISA wells 6 times with wash buffer (concentrate diluted 1:20).  Please 
refer to package insert for more detailed instructions for washing plates. 
11. Tap ELISA plates face down on absorbent paper to remove residual wash buffer. 
12. Dilute the required amount of Chromogen 100X Concentrate in Enzyme Substrate 
Buffer (as shown in Table 2) and add 100 µl of freshly prepared enzyme substrate 
solution to each well.  Begin timing the incubation when substrate is added to first 
well. 
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 TABLE 2. SUBSTRATE Preparation Table 
# of Strips Volume of  Chromogen 
100x Concentrate 
Volume of 
Substrate Buffer 
   
1 10 µL 1 mL 
2 20 µL 2 mL 
3 30 µL 3 mL 
4 40 µL 4 mL 
5 50 µL 5 mL 
6 60 µL 6 mL 
7 70 µL 7 mL 
8 80 µL 8 mL 
9 90 µL 9 mL 
10 100 µL 10 mL 
11 110 µL 11 mL 
12 120 µL 12 mL 
 
13. Place the lid on the ELISA plate and mix with a microplate shaker for 1 min with 
waveform set at 20 and amplitude set at 6. 
14. Incubate away from direct sunlight at room temperature for precisely 30 min.   
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 15. Add 50 µl of Enzyme Stopping Solution to each well.  Enzyme Stopping Solution 
should be added to wells in the same order and at the same speed as the substrate in 
step 12. 
16. Place the lid on the ELISA plate and mix gently on a microplate shaker or in the 
ELISA instrument. 
17. Read the absorbance (optical density) of each well at 450nm (with a 620nm reference 
filter) using an ELISA plate reader within 5 min of adding the stopping solution. 
18. Print absorbance readings from the ELISA plate reader and attach to ELISA 
worksheet.  
*19. Use the QuantiFERON-CMI Analysis Software supplied by Cellestis to do the 
following: 
a. Determine the mean absorbance values for each of the standard IFN-γ samples 
and construct a linear standard curve with IU/ml IFN-γ versus absorbance.  
b. Assess the validity of the ELISA test. 
c. Convert the absorbance value of each test plasma into IFN-γ IU/ml using the 
standard curve.     
20. Keep paper and electronic copies of the ELISA worksheet and the IFN-γ results. 
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 21. Immediately report any episodes where 2 QFT-CMI ELISAs fail in a row, or if more 
than 1 in any series of 10 fails.  Await technical input before running additional 
ELISAs. 
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 QFT-3G ELISA Worksheet 
 
IFN- ELISA assay 
number: 
  Date of assay:         
    mont
h 
day Year 
Lab:  __________________________   Operator(s): ________________________ 
 
QuantiFERON Kit (Batch number): __________________ 
 
ELISA Plate Setup:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A N(1) T(1) M(1) N(9) T(9) M(9) 
N(17
) T(17) M(17) N(25) 
T(25
) 
M(25
) 
B N(2) T(2) M(2) N(10) T(10) M(10) 
N(18
) T(18) M(18) N(26) 
T(26
) 
M(26
) 
C N(3) T(3) M(3) N(11) T(11) M(11) 
N(19
) T(19) M(19) N(27) 
T(27
) 
M(27
) 
D N(4) T(4) M(4) N(12) T(12) M(12) N(2) T(20) M(20) N(28) 
T(28
) 
M(28
) 
E N(5) T(5) M(5) N(13) T(13) M(13) N(2) T(21) M(21) S1 S1 S1 
F N(6) T(6) M(6) N(14) T(14) M(14) N(2) T(22) M(22) S2 S2 S2 
G N(7) T(7) M(7) N(15) T(15) M(15) N(2) T(23) M(23) S3 S3 S3 
H N(8) T(8) M(8) N(16) T(16) M(16) N(2) T(24) M(24) S4 S4 S4 
N = NIL QFT-3G plasma, T= TB antigen stimulated QFT-3G plasma, and M=Mitogen 
stimulated QFT-3G stimulated plasma;  Numbers in parentheses indicate samples from 28 
different patients (1) through (28). Example: N(1) = Nil QFT-3G plasma from first subject's 
blood sample; and S1 through S4: High Standard to Zero Standard for IFN-γ.     
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 Appendix 2 (continued) 
 
   
Subject Numbers  Sample Incubation 
1  9  17  25   Start Time Stop Time 
2  10  18  26     
3  11  19  27   Start Temp Stop Temp 
4  12  20  28     
5  13  21  Standard Conc.   
6  14  22  S1   Substrate Incubation 
7  15  23  S2   Start Time Stop Time 
8  16  24  S3     
      S4     
 
Printouts attached:  
 YES  NO  
Absorbance readings from plate reader:     
     
Calculations IU/mL (Excel spreadsheet):     
 
Electronic Results File: ________________________________________ 
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